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Botulinum neurotoxins (BoNTs) cause the lethal disease botulism through the inhibition 
of acetyl choline secretion by the cleavage of crucial SNARE proteins. Determination of 
critical residues in the protein sequence of BoNT serotype A was the primary step to identify 
novel fluorescence recognition agents for BoNTA. Computational and experimental studies 
were employed to identify paclitaxel as a new inhibitor (IC50 equal to 5.2 µM) for the 
proteolytic activity of BoNTA light chain (LC) using Fluorescence Resonance Energy 
Transfer (FRET) assay. A fluorescent derivative of paclitaxel (PAC-BDP) exhibited binding 
to complex BoNTA. A Primary Amines Database comprised of 1,153 compounds suitable for 
fluorescent labeling was computationally screened to select 6-aminofluorescein (6-AFLU) and 
aspartame (APM) as recognition agent candidates. Fluorescent labeled APM (APM-BDP) was 
synthesised and the purity of the compound was confirmed using liquid chromatography mass 
spectrometry (LC/MS) and nuclear magnetic resonance (NMR). 6-AFLU exhibited good 
binding affinity to BoNTA heavy chain (HC) with an EC50 of 546 ± 60nM, whereas APM-
BDP displayed binding to BoNTA LC with an EC50 of 20.96 ± 10 nM, as determined by 
fluorescence polarization (FP) assay. APM was shown to compete with APM-BDP for the 
same binding site in BoNTA LC, but showed no binding to BoNTA HC in FP competition 
assay. Also, aminopterin (AMN) and 6-AFLU exhibited binding to the same site of BoNTA 
HC, whereas desmosine (DES) showed affinity to a different binding site in BoNTA HC. 
Additionally, PAC exhibited binding to BoNTA LC, however paclitaxel (PAC) did not 




BoNTA LC and BoNTA HC and did not compete with APM-BDP for the same binding site in 
BoNTA LC. A library consisting of 1,624 commercially available radiolabeled ligands were 
screened computationally to select the ligands with binding affinity against BoNTA LC and 
HC. The binding of [
3
H] Aminopterin and [
3
H] desmosine was shown to be concentration-
dependent with EC50of 703 ± 98 nM and 1.6 ± 0.3µM, respectively, against BoNTA HC using 
scintillation proximity assay (SPA). [
3
H]Solanesyl pyrophosphate (Solanesyl PP) exhibited 
high binding to both BoNTA LC and BoNTA HC. However its related compound, 
[
3
H]Solanesol, show no binding against BoNTA LC or BoNTA HC using SPA assay.  
The development of a fast, simple, reliable assay for BoNTA detection is essential since 
mouse lethality assay (MLA), the only trustable assay, is a costly, time consuming and 
complicated assay. In addition, detection of BoNTA in the initial steps of contamination is 
critical for successful treatment. This study demonstrated that FP can be used as a platform for 
BoNTA detection and that PAC-BDP, APM-BDP and 6-AFLU can be used simultaneously 
since they bind to different binding regions of BoNTA. The identified recognition agents can 
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1 CHAPTER ONE: INTRODUCTION 
1.1 INTRODUCTION 
There are four important pathogen species in Clostridium genus including Clostridium 
perfringens, Clostridium tetani, Clostridium difficile and Clostridium botulinum. C. botulinum is 
an obligate anaerobic, gram positive and spore forming bacillus. These bacteria are found in soil 
and grow at 37 °C or 30 °C, pH 6.5-7.0. The bacterium 
1
 generates spores in unfavourable 
conditions to survive. C. botulinum produces toxin known as botulinum neurotoxin (BoNT). 
There are seven types of the toxin classified by the letters A through G. Human botulism is 
caused by toxin type A, B and E, whereas type F is implicated less often. Type C and D cause 
botulism in non-human species and type G never has been found to cause botulism in humans.
2
 
1.1.1 Chemical structure of the toxin 
BoNT is one of the most poisonous known toxins. Based on primate studies the lethal oral 
dose of BoNTA for a 70 kg human is estimated at 70 µg.
3
 BoNT is a complex consisting of 
botulinum neurotoxin and nontoxic associated proteins (NAPs). The NAPs consist of 
hemagglutinins (HA) and a nontoxic nonhemagglutinin (NTNH). The number of NAPs is 
variable between two to six in different serotypes of BoNT. NAPs are protecting BoNTs from 
protease and acidic environment and also assist BoNT to cross the intestinal epithelial barrier. 
4
All clostridial neurotoxins are synthesized by the bacteria as a single inactive polypeptide chain 
with a molecular weight about 150 kDa. These neurotoxins remain inactive after synthesis. 








1.1.2 Mechanism of action of the toxin 
The routes of administration of BoNT include ingestion, inhalation and wound. The 
BoNT starts its journey after entering to the body and absorbs through mucosal surfaces such as 
digestive and respiratory systems. Consequently, the BoNT enters the lymphatic system and 
blood circulation. Ultimately, BoNT reaches a nerve cell and binds to the ganglioside molecule 
on the cell surface of the nerve cells, which is followed by receptor-mediated endocytosis. The 
BoNT HC plays two roles including receptor binding through its C-terminus to nerve cells, and 
translocation of the light chain into the cytoplasm across the membrane through its N-terminus
5
. 
The BoNT LC exhibits zinc-endopeptidase activity and cleaves soluble NSF-attachment protein 
receptor (SNARE) proteins. SNARE proteins include synaptobrevin, syntaxin and SNAP-25. 
These proteins are essential for the secretion of neurotransmitters 
6
. The synaptobrevins are 
located on synaptic vesicles and syntaxin and SNAP-25 are the plasma membrane proteins.  Any 
SNARE proteins degradations disrupts formation of functional SNARE proteins complex and 
blocks acetylcholine’s exocytosis and lead to paralysis. The target protein of BoNTA, C and E is 
SNAP-25 (synaptosomal associated protein) with 25 kDa molecular weight while the BoNTB, D, 
F and G cleave synaptobrevin as a target 
2, 7
.  
1.1.3 Clinical symptoms 
Double vision, dry mouth, dilated pupils, difficulty of speaking, muscle weakness, and 
flaccid paralysis are some early symptoms of botulism. Limb and respiratory muscle paralysis 
are the secondary symptoms of botulism, which can lead to death. The symptoms usually 




BoNT, recovery time will be different 
8
. The current treatment of the BoNT is an antitoxin 
combined with respiratory supportive care. However, the treatment must be applied before BoNT 
reaches nerve cells because BoNT is not accessible after entering the nerve cell cytoplasm 
9
.  
1.1.4 Clinical forms 
Foodborne, wound, infant, adult infectious, and inadvertent are five clinical forms of 
botulism. Foodborne botulism is caused by ingestion of contaminated food by preformed toxin. 
In infant and adult infectious botulisms, ingested organisms produce toxin in the digestive 
system. The infant intestine does not have protective bacterial flora before the age of 6 months. 
The presence of clostridial spores in honey products has been reported; thus honey should not be 
given to children during the first year of life 
10
. However, in wound botulism the organisms grow 
in deep wound and produce toxin. Inadvertent botulism occurs in people with movement 
disorders who were treated with intramuscular injections of BoNT 
1-2
.  
1.1.5 BoNT detection methods 
Many studies have been done to improve methods for BoNT detection due to the necessity 
of developing a rapid method to diagnose botulism. Table 1.1 summarizes some of the detection 
methods including mouse lethality assay (MLA), lateral flow assay (strip assay or Immuno-
chromatographic assay), enzyme-linked immunoassays (ELISA), polymerase chain reaction 
(PCR), immuno-PCR detection, fluorescence polarization immunoassay (FPIA), cellular based 
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1.1.6 Mouse lethality assay (MLA) 
Mouse lethality assay is based on an intraperitoneal (IP) injection of a sample into 
laboratory mice. If the sample contains the toxin, mice show botulism symptoms. The minimum 
amount of the toxin which kills all the incubated mice is called mouse lethality dose (MLD). The 
sensitivity of the assay is 1 MLD for BoNTA, which is equal to 10 pg/ml of the toxin. The assay 
is the most sensitive method for BoNT detection, and also is able to identify all seven toxin 
serotypes. MLA has been used to detect the toxin indifferent samples such as serum, wound, 
gastric and food 
8
. Although  MLA is the only trustable assay for toxin detection, it has several 
disadvantages such as being costly, laborious, and slow as well as ethical issues (Table 1.1) 
2
. 
1.1.7 Fluorescence polarization assay 
FP is a powerful method that has been used for molecular interaction studies. This assay is 
based on movement and rotation of a fluorescent molecule in solution while the viscosity and 
temperature of the solution are constant. The fluorescence polarization is enhanced by increasing 
the solvent viscosity and decreasing the temperature. The emitted light of a large fluorescent 
molecule after excitation with plane polarized light, remains highly polarized due to slow 
movement of a large molecule in the excitation state. However, in the case of small fluorescent 
molecules the emitted light will be depolarized due to fast rotation of the molecule in the 
excitation state
15
. Therefore, changes in polarization intensity can be measured. The excitation 
state is the period of time between absorption of excitation photon and emission of a photon by 
the fluorescent molecule 
14b, c
. The emitted polarization value for the free small fluorescent 
molecule will be low while the emitted polarization value for the small fluorescent molecule 
bound to a large molecule will be high 
14c





mP = 1000 [ FLUpar – FLUper] / [FLUpar + FLUper] 
In this equation, P is polarization (given in unites of milli polarization) , FLUpar is the 
parallel fluorescence intensity measurement and FLUper is the perpendicular fluorescence 
intensity measurement. P (polarization) is independent of the fluorophore concentration and the 
value of emitted light.  
FP is a homogenous assay that shows molecular interactions especially binding event in 
solution. Separation and washing steps are not required for FP assay making it faster, easier, 
cheaper and more accurate than other assay platforms for ligand binding. The reaction’s 
equilibrium is disrupted in assays that require separation steps thus decreasing the assay accuracy 
14c
. Also FP assay has high sensitivity and is suitable for high throughput screening. 




1.1.8 Fluorescence resonance energy transfer (FRET) 
Another fluorescent based assay which has been used in many fields for molecular 
interaction studies is FRET assay. This assay utilizes fluorescent substrate to explore the binding 
interactions of molecules 
7, 17
. Lately the FRET substrate peptide SNAPtide® was employed by 
several researchers to identify new inhibitors for BoNTA. SNAPtide is a synthetic peptide 
substrate and consists of a quencher and a fluorophore at the C-terminus and N-terminus, 
respectively. The cleavage site of SNAPtide is similar to SNAP-25 which is the native substrate 
of BoNTA. BoNTA LC cleaves SNAPtide and releases the fluorophore 
7, 18
. The value of 
fluorescence intensity shows the enzymatic activity of BoNTA. In the presence of inhibitors, the 




unoccupied active sites available for substrate binding. Consequently, the fluorescence intensity 
is reduced by increasing the concentration of inhibitor 
19
.  
1.1.9 Scintillation proximity assay 
Scintillation proximity assay (SPA) is one of the homogenous, high sensitive and accurate 
methods to investigate molecular interactions in the biochemistry field, especially in enzyme and 
protein ligand interaction assays. This homogeneous assay only requires adding and mixing 
reagents as well as measuring the response without any separation or filtering steps
20
. However 
SPA is an expensive assay due to use of radio-isotopes. The principle of SPA technology is 
based on the distance between two molecules in solution. Prior to design SPA assay one of the 
involved molecules (protein) in the interaction is required to be labeled by biotin. The 
biotinylated molecule shows strong affinity to scintillant beads coated with streptavidin
20
. The 
interaction of radiolabeled molecule and biotinylated protein decreases the distance of scintillant 
beads and radiolabeled molecule. In this stage, decay of radiolabeled molecule can stimulate the 
scintillant contained inside the bead to emit light, and the emitted light can be measured by a 









P radio-isotopes. The radioactive molecule decays particles and the 
particles travel different distance according to their environment and their energy
21
.  
1.1.10 Computer-aided molecular design 
1.1.10.1 Virtual screening 
Virtual screening has become an essential component of biochemistry and drug 




from chemical databases against any particular target.  Ligand-based and structure-based are the 
two major approaches of virtual screening
22
.  
1.1.10.2 Pharmacophore modeling 
A pharmacophore model is a 3D arrangement of essential functional groups for interaction 
with the target. The pharmacophore approaches facilitated identification of lead compounds in 
biochemistry and drug discovery 
23
. A pharmacophore can be derived by employing ligand-based 
or structure-based pharmacophore modeling. The ligand-based pharmacophore modeling, 
structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) 
are the main methods of ligand-based virtual screening approach. These methods are utilized to 
search for similarity in the structure of ligands to optimize the lead compounds. Ligands with 
similar structure to an active compound are often active themselves. The structure-based 
approaches depend on the knowledge of the 3D structure of the target protein free or bound to 
the ligand
24
. This valuable information is used for the molecular docking of ligands. Both ligand-




1.1.10.3  Molecular docking 
Molecular docking enables us to predict binding interactions of protein-ligand, protein-
DNA and protein-protein. This approach provides the ability of screening a large library of 
compounds for their binding against the target protein 
25
. Molecular docking approach evaluates 
the interaction of potential ligands to the target and calculates the binding energy of ligand using 
molecular mechanics. Molecular docking searches for best conformation and orientation of 
ligand in the particular binding site and calculates binding affinity (scoring)
26,27




HierVLS is a computational approach to screen large libraries of chemical compounds 
rapidly. This approach enables us to determine the binding interaction of each ligand against 
each one of the available binding pockets of a protein.  In this approach, the binding energy of 
each ligand to each binding region calculated and the ligands were ranked based on their binding 
energies to select best candidates. HierVLS approach is comprised of the following steps 
including Level 0, Filter, Level 1 and Level 2. The numbers of configuration is generated for 
each ligand against each binding site of protein in Level 0. During the Filter step, the percentage 
of buried surface area and the number of hydrogen bonds between ligand and target calculated 
for each configuration. The configurations were ranked based on docking scores, buried surface 
area and the number of hydrogen bonds. The best numbers of configuration of each ligand were 
energy minimized at Level 1 and the configuration with lowest energy is selected for an all-
atoms energy minimization at Level 2.  
 The Cassandra GUI 
28 
was used to import the input files (ligands and protein files) and 
organize the input and output files. HierVLS comprise of the following major software 
programs, PASS, Dock 4.0, DMS, HBplus, Connolly, and Open Babel 
29
. Open Babel is utilized 
to convert the file formats between programs. PASS program is used to identify potential binding 
pockets within the protein. Dock 4.0 is used to generate a large number of configurations (> 
10,000) for each ligand bound to each binding region. The molecular surface, accessible surface 
area and number of hydrogen bonds of between protein and ligand are determined using DMS, 
Connolly, and HBplus software programs, respectively.  
 This method increases the accuracy of screening because the number of generated ligand-
protein configurations for each ligand-protein pair decrease while the time required for 




HierVLS . The binding energy of the best configuration of each ligand calculated at the end.  The 
force field binding energy for each binding region (i) calculated using the following equation: 
                                                                        
Where FF_BEi is force-field binding energy, PE represents potential energy, and SE is solvation 
energy. Compounds with more negative binding energy consider as potential active ligands. 
Additionally, the force-field binding energies were used to calculate Holistic Binding score using 
the following equation: 
            
      
∑       
 
   
 
Where HBSi is the holistic binding score for a particular ligand bound to region i, and n 
represents the number of binding regions. The result of this approach is a set of ligands ranked 
by binding affinity for a particular binding site relative to all other potential sites within the 
target protein.  
1.1.10.4Data processing and statistical analysis 
In this thesis, all the data was analysed using Graphpad prism 6 (www.graphpad.com). 
Whenever appropriate, the experimental data was analysed using two way ANOVA. The two 
way ANOVA analysis is based on the assumption that the replicates are sampled from Gaussian 
distributions and determines how a response is influenced by two factors.  
To determine whether the difference between two samples is statistically significant or not, we 
compared the mean of each sample (averaged over duplicate or triplicate measurements) to the 
mean of its related control in each row. There are two values that determine a test of 




Alpha level is the probability of getting the wrong result, and shows the level of confidence of 
the experiment. If the alpha level is set at 0.05, we would expect to get the same result 95 times 
out of 100 times repeating the experiment. The P value is the probability of getting the observed 
result. The smaller the p value, the greater is the statistical significance of the result. To conclude 
that the observed value did not occur by chance, the P value should be equal or less than the 
alpha level. In this study the alpha level was set at 0.05 to have the confidence interval of 95%. P 
value for each comparison was displayed as stars in the bar graphs. The four, three, two, and one 
stars represented P value lower than 0.0001, 0.001, 0.01 and 0.05, respectively.  
 
 
1.2 RESEARCH OBJECTIVES 
1.2.1 Long-term objective 
This study is part of a long-term program to develop a multi-probe fluorescence-based 
detection assay for the BoNTA. Fluorescence Polarization as a fast and reliable detection assay 
will be used for BoNTA detection. In addition, new fluorescent recognition agents for BoNTA 
will be identified through the application of computer-assisted drug design techniques. 
 
1.2.2 Specific aims of this study 
1) Use computer-assisted drug design techniques (CADD) to identify recognition agents 
for BoNTA detection, with emphasis on fluorescent ligands. 
2)  Assess Fluorescence Polarization as assay platform for the development of a fast and 
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2 CHAPTER TWO: STRUCTURAL AND 
SEQUENCE ANALYSIS OF BoNT 
SEROTYPES (A-G) AND BoNTA 
SUBTYPES 
2.1 INTRODUCTION 
Structural analysis of different subtypes of BoNTA will improve our understanding of their 
structural features. Additionally, this study can enhance our knowledge of different BoNT 
serotypes (A-G) which is useful in the design of subtype-specific assays. The goal is to identify 
critical regions that may differentiate BoNT subtypes for detection methods. In this project, 
bioinformatics tools and database information were utilized to determine regions of high and low 
similarity between different subtypes of BoNTA (A1, A2, A3 and A5), and also different 
serotypes of BoNT (A, B, C, D, E, F, and G).  
2.2 METHODS AND PROCEDURES 
2.2.1 Sequence and structural analyses of BoNTA subtypes 
2.2.1.1 boNTA1 gene 
The information about boNTA1 gene was obtained from the National Center For 
Biotechnology Information (NCBI) gene bank 
1
. Three BoNTs were found using the NCBI and 
searching for boNTA1 gene. These included (1) botulinum neurotoxin type A1 from Clostridium 
botulinum A str. Hall, (2) botulinum neurotoxin type A1 from Clostridium botulinum F str. 
Langeland and (3) botulinum neurotoxin type A1 from Clostridium botulinum A str. (ATCC 




for further analysis 
2
. The information about boNTA gene was found using the “botulinum 
neurotoxin type A1 [Clostridium botulinum A str.Hall]” link. The gene product information was 
obtained from “UniportKB/Swiss-Prot” link under “mRNA and Protein” 
1
. 
2.2.1.2 The amino acid sequence of boNTA1  
The amino acid sequence of BoNTA (accession number: A5HZZ9) was obtained from 
“UniportKB” database of the ExPASy (Export Protein Analysis System) proteomics server 
website. The protein sequence is shown in Figure 2.1. 
2.2.1.3 BLAST search 
Database similarity search with the BoNTA amino acid sequence was performed using 
BLAST search. The goal of this step was to search for similarity between BoNTA sequence and 
other sequences in the database to find homologous proteins. The UniportKB database of the 
ExPASy website was used for BLAST search. The parameters for BLAST search were as 
follow: substitution matrix: BLOSUM-62, threshold: 10, filtering: filter low complexity region, 
gap: was considered, and hits: 100. 
2.2.1.4 Multiple sequence alignment 
To identify regions of similarity and diversion between different subtypes of BoNT, a 
multiple sequence alignment was performed. The amino acid sequences of BoNTA were saved 
into a single file in fasta format, readable by the alignment program, Clustal
3
. The multiple 
sequence alignment was run using Clustal x with the following parameters: substitution matrix: 




2.2.1.5 Identification of conserved motifs  
Motifs, domains and pattern are used to classify proteins into functional families. A pattern 
is a small part of sequence with distinct amino acids at specific position. This region is conserved 
within a family of proteins. The PROSIT, PRINTS, and PFAM were used to identified pattern, 
motifs and domains of BoNTA 
4
.   
2.2.1.6 3D structure of BoNTA 
To analyze BoNTA 3D structures, first the complete structure of BoNTA was obtained 
from the protein data bank. 2NYY and 3BTA were two choices of complete structure of BoNTA.  
In this study 3BTA structure was selected for this structural analysis. The program VMD
5
 was 
used to visualize the BoNTA 3D structure and identify critical regions of the protein 
6
. Also, 
variable residues obtained by multiple alignment of the different subtypes of BoNTA (Table 2.1) 
were visualized within the structure in order to better examine the variable regions. 
2.2.1.7 Quality of the protein structure 
The Procheck (www.ebi.ac.uk) and Whatcheck (www.ebi.ac.uk) programs were used to 
analyze the structure 3BTA in term of chirality, hydrogen bonds, torsion angles, missing atoms 
and segments 
7
. This was performed to assess the quality of the structure. 
 
2.2.2 Sequence and structural analyses of BoNT serotypes 
2.2.2.1 The amino acid sequence of BoNT serotypes 
The amino acid sequences of BoNT serotypes (A-G) were collected from “UniportKB” 
database of the ExPASy (Export Protein Analysis System) proteomics server website to use as 






2.2.2.2 BLAST search 
The BoNT serotype amino acid sequences were obtained through a database similarity 
search using BLAST. This step is necessary to identify similarities between BoNT serotype 
sequences. The BLAST search result contains two parameters to determine the significance of 
the hits including score and expectation value (e-value). Higher score indicates higher similarity 
of the amino acid sequences and very small value of e-value (≤0) confirms that blast search is 
statistically significant. The UniportKB database of the ExPASy website (www.expasy.org) was 
used for BLAST search. The parameters for BLAST search were as follow: substitution matrix: 
BLOSUM-62, threshold: 10, filtering: filter low complexity region, gap: was considered, and 
hits: 100.  
2.2.2.3 Multiple sequence alignment 
A multiple sequence alignment was performed to determine regions of high and low 
similarity between the different BoNT serotypes. The multiple alignment was also used to 
highlight important regions for discrimination between BoNT serotypes. The amino acid 
sequences of the different BoNT serotypes were saved into a single file in fasta format readable 
by Clustal. The multiple sequence alignment was run using Clustal x with the following 
parameters: substitution matrix: BLOSUM30, gap Opening penalty: 10, and gap extension 
penalty: 0.10. 
2.2.2.4 Identification of conserved motifs  
The PRINTS database was used to find conserved motifs between BoNT serotypes 
9
. Also, 
PFAM and PROSITE were searched to determine domains and patterns within the sequence of 
BoNT serotypes 
4




2.2.2.5 Visualization of variable residues in BoNT serotypes 
As mentioned in the section 2.1.6. (3D structure of BoNTA), the 3D structure of BoNTA 
and variable residues obtained by multiple alignment (Table 2.5) were used to visualize the 
variable regions of the different serotypes of BoNT.  
2.3 RESULTS &DISCUSSION 
2.3.1 Sequence and structural analyses of BoNTA subtypes 
2.3.1.1 boNTA1 gene 
boNTA1 (accession number: A5HZZ9) encodes for botulinum neurotoxin type A 
(BoNTA). Botulinum neurotoxin type A binds to the largest luminal loop of the secretory vesicle 
protein SV2 (SV2A, SV2B, and SV2C) and then enters the cytoplasm. The heavy chain is 
responsible for binding to nerve cell receptors and transferring the light chain into cytoplasm. 
The light chain is responsible for cleavage of SNARE proteins (including SNAP25, 
synaptobrevins, and syntaxin) at 197-Gln-|-Arg-198 location which blocks neurotransmitter 
release. The light chain’s catalytic mechanism is a metalloprotease which needs a zinc for its 
catalytic activity 
10
. BoNTA belongs to the peptidase M27 family and contains 1296 amino acids. 
The light chain starts from amino acid number 2 to 448 (447 AA length) and the heavy chain 
starts from amino acid 449 to 1296 (848 AA length). BoNTA contains two transmembrane 
regions and each region consists of 21 AA. One of the transmembrane regions begins from 
amino acid 627 to 647 and the other one starts from amino acid 656 to 676 (Figure 2.2). The 
amino acid number 224 is in the active site and amino acids numbers 223, 227, and 262 are metal 
binding sites (Figure 2.3). The two disulfide bonds which are connecting light chain to heavy 




experimental data, the amino acid 1218 (S→Y) is a sequence conflict and a fully active BoNT is 
extends at least up to 1218 amino acids
10
.  
2.3.1.2 The amino acid sequence of BoNTA1 
The amino acid sequence of BoNTA1 in fasta format is shown in Figure 2.1. 
 
>sp|A5HZZ9|BXA1_CLOBH Botulinum neurotoxin type A OS=Clostridium botulinum 
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2.3.1.3 BLAST search 
Amino acid sequence of BoNTA1 (accession number: A5HZZ9) was used as query for a 
BLAST search. Based on the BLAST result about 25% of the hits had more than 90% similarity 




with 40% identity. The E-values for all the sequences were equal to 0.0, thus the BLAST search 
was statistically significant. The score values for the 25% (with high identity) were between 
6710-5700. The10 hits with the similarity more than 90% were chosen for further analyses. 
Table 2.1 summarizes the information related to the selected 10 hits.    
2.3.1.4 Multiple sequence alignment 
Multiple sequence alignment of the 10 selected hits was performed using Clustal. Based on 
the multiple sequence alignment, the selected 10 sequences showed high similarity as expected. 
The variable amino acids, weakly and strongly conserved residues as well as strongly conserved 
regions are summarizes in the Table 2.2. The critical regions of the BoNTA sequences were 
found based on the information obtained from sequence annotation feature of the ExPASy 
proteomics server website 
10
 and the multiple alignment. As shown in the Figure 2.2, the 
transmembrane regions of the selected 10 BoNTA amino acid sequences are fully conserved. 
Each conserved helical transmembrane region contains 21 amino acids. The first region starts at 
amino acid 627 and ends at 647 and the second one starts at amino acid 656 and ends at 676. The 
active site (Glu224) and zinc binding sites (His223, His227 and Glu262) in the 10 selected 
BoNTA were also fully conserved (Figure 2.3) which is in accordance to studies by Arndt (2006) 
11
. As shown in the Figure 2.4, the four amino acid cysteines (430, 454, 1235 and 1280) 











Table 2.1 The information of the 10 selected protein sequences with high similarity to BoNTA 
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A (BoNTA) (EC 3.4.24.69) 
(Bontoxilysin-A) (BOTOX) 
[Cleaved into: Botulinum 
neurotoxin A light chain; 
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A (BoNTA) (EC 3.4.24.69) 
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neurotoxin A light chain; 
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2, 14, 41, 50, 57, 92, 109, 110, 140, 154, 163, 169,215, 229, 264, 269, 278, (283 -286), 295, 296, 319, 332, 
336, 337, 348, 352, 357, 382, 387, (397– 401), 406, 411, 437, 478, 496, 515, 530, 567, 581, 593, 601, 602, 
607, 624, 648, 654, 663, 671, 713, 775, 779, 832, 874, 882,899, 900, 905, 993, 994, 1006, 1156, 1232, 1254, 





11, 28, 121, 122, 141, 142, 152, 166, 170, 194, 212, 239, 309, 319, 339, 347, 381, 393, 394, 410, 436, 505, 
572, 580, 582, 589, 598, 605, 619, 650, 661, 707, 767, 804, 818, 880, 885, 887, 895, 902, 908, 923, 954, 955, 






29, 40, 42, 70, 76, 96, 113, 137, 139, 159, 162, 164, 171, 173, 220, 243, 246, 252, 260, 269, 271, 272, (279-
281),(288-293), 299, 301, 303, 308, 316, 322, 328, 329, 331, 334, 335, 340, 341, 343, 344, 349, 353, 356, 361, 
375, 388, 395, 344, 352, 376, 415, 444, 452, 476, 483, 507, 546, 556, 573, 578, 591, 592, 594, 604, 609, 622, 
634, 635, 647, 651, 656, 657, 659, 664, 667, 668, 672, 673, 676, 681, 685, 686, 696, 726, 730, 734, 735, 744, 
789, 809, 815, 816, 831, 835, 840, 847, (858-861), 876, 881, 884, 886, 896, 897, 903, 906, 907, 915, 917, 926, 










1,(3-10), (12-13), (15-26), 28, (30-39), (43-50), (51-56), (58-69), (71-75), (77-91), 93, 95, (97-101), (103-108), 
111, 112, (114-120), (123-136), 138, (143-151), 153, (155-158), 160, 161, 165, 167, 168, 172, (174-193, (195-
211), 213, 214, (216-219), (221-228), (230-238), (240-242), 244, 245, (247-253), (255-259), (261-263), (265-
267), 270,( 273-277), 282, 287, 294, 297, 298, (300-301), 303, (305-307), (310-315), 317, 320, 321, (323-326), 
329, 330, 333, 338, 342, 345, 346, 350, 351, 354, 355, (358-360), (362-380), (383-386), (389-392), 396, (501-
504), 506, (508-514), (508-514), (516-529), (531-545), (547-559), 561, (564-566), (568-571), (574-577), 579, 
623, (625-632), (635-646), 649, (652-653), 655, 658, 660, 662, 665, 666, 669, 670, 674, 675, (677-680), (682-
684), (687-695), (696-706), (708-712), (714-719), (721-725), (727-729), (731-733), (736-743), (745-766), 
(768-774),(776-778), (780-788), (790-803), (805-808), (810-814), 817, (819-830), 833, 834, (836-839), (841-
846), (848-857), (862-873), 875, (877-879), 883, (888-894), 898, (909-914), 916, (918-922), 924, 925, (927-
929), (931-947), (949-953), 956, (958-967), (969-989), (995-1004), (1007-1014), 1016, (1018-1023), (1027-
1051), (1053-1062), (1065-1067), (1069-1079), (1081-1089), (1091-1093), (1095-1102), (1104-1109), (1111-
1116), (1118-1127), (1129-1140), (1145-1152), 1154, 1155, (1157-1169), (1171-1207), (1209-1226), (1228-











Figure 2.2 Multiple alignment of the 10 selected BoNTA subtypes. The transmembrane regions 











Figure 2.3 Multiple sequence alignment of the 10 selected BoNTA subtypes. The active site and 






    
Zinc binding site Zinc binding site 
 














Figure 2.4 Multiple alignment of the 10 selected BoNTA subtypes. The conserved amino acids 
(cysteine) involved in disulfide bonds are shown by the arrows. 
 
2.3.1.5 Identification of conserved motifs  
The BoNTA was characterized by the zinc protease motif pattern using PROSITE. The 
results showed that BoNTA belongs to peptidase M27 family and zinc-binding region signature 
is as follow [G S T A L I V N ] - { P C H R } - { K N D } - H - E - [ L I V M F Y W ] -
{ D E H R K P } - H - { E K P C } - [ L I V M F Y W G S P Q ] . This bracket [] in pattern sequence 
means a protein sequence required to have any amino acids at this specific position except the 
amino acids listed inside the bracket [] to be a member of this family. This bracket {} of pattern 
sequence means either one of the amino acids listed inside the bracket should be available at this 
specific position to consider a protein as a member of this family. PRINTS and PFAM databases 
were searched to identify motifs and domains within BoNTA sequence. The number of motifs 
and domains were six (1-6) and four, respectively. The four BoNT domains are peptidase_M27, 
transmembrane, N-terminal and C-terminal domains 
9, 12
.     




2.3.1.6 3D structure of BoNTA 
The 3D structure of BoNTA was visualized using 3BTA pdb file in VMD and presented in 
the Figure 2.5. The amino acids in the active site involved in zinc coordination are shown in the 
Figure 2.5A. Additionally the amino acids involved in disulfide bonds are presented in Figure 
2.5B and C. The resolution of 3BTA crystallography structure was 3.20 Å. BoNTA consists of 
19 α-helices and 54 β-strand regions which were obtained from analyzing the 3D structure using 
VMD. The variable residues between BoNTA subtypes obtained based on the multiple alignment 













Figure 2.5 The 3D structure of BoNTA. A, represents the amino acids in the active site involved 
in zinc coordination (sphere is representing the zinc atom). B and C, represent the four amino 
acids involved in disulfide bonds. 
 
 
Figure 2.6 Variable residues identified between BoNTA subtypes. The red colors represent the 
variable residues found in BoNTA subtypes using multiple sequence alignment. The yellow and 
purple colors represent β-strands and α-helices, respectively. 
 
2.3.1.7 Quality of the protein structure 
The Psi/Phi angles for the 3BTA structure are concentrated in “most favoured regions” of 
the Ramachandran plot. The number of Glycine and Proline in the 3BTA structure is 62 and 38, 
respectively 
13
. Based on Whatcheck analysis report, there are two missing residues in the 3BTA 
structure which are Asparagine 432 and Arginine 431. Increasing the number of missing atoms 
will decrease the sensitivity of the structure quality check. The number of reported unsatisfied 
hydrogen bond donors and unsatisfied hydrogen bond acceptors in the structure were 25 and 4, 
respectively. These hydrogen atoms are not involved in H-bond network. Less unsatisfied H-




and also all 3BTA protein atoms have proper chirality 
14
. According to the previous information, 
the overall quality of 3BTA structure was reasonable.  
 
2.3.2 Sequence and structural analyses of BoNT serotypes 
2.3.2.1 The amino acid sequence of BoNT serotypes   
The critical regions of the BoNT serotype sequences were found based on the obtained 
information from the sequence annotation feature of the ExPASy proteomics server website. 
These features are including the length of the light and heavy chains, transmembrane regions, 
active sites, metal binding sites and the residues involved in disulfide bonds. Table 2.3 
summarizes these features of the BoNT serotypes.  
2.3.2.2 BLAST search 
The amino acid sequences for the different BoNT serotypes A-G were obtained through a 
BLAST search using amino acid sequence of BoNTA (accession number: P10845) as the query. 
The BLAST search was statistically significant because the e-value for each pair was equal to 
0.0. The score values were between 6710-1700. The similarity and identity percentages of 
sequences were more than 50% and 31%, respectively. The BLAST search of the different 


























Light Chain 2-448 1-436 2-442 2-422 2-441 1-442 - 
Heavy chain 449-1296 437-1274 443-1297 423-1251 442-1291 443-1276 - 
Transmembrane Region 627-647 
656-676 
- - 638-658 653-673 - - 
Active site 224 228 231 213 231 230 - 














































































































length 1296 1274 1297 1251 1291 1276 1280 
References 



































Botulinum neurotoxin type A 
(BoNTA) (EC 3.4.24.69) 
(Bontoxilysin-A) (BOTOX) [Cleaved 
into: Botulinum neurotoxin A light 





























Botulinum neurotoxin type F (BoNTF) 
(EC 3.4.24.69) (Bontoxilysin-F) 
[Cleaved into: Botulinum neurotoxin F 































Botulinum neurotoxin type G 
(BoNTG) (EC 3.4.24.69) 
(Bontoxilysin-G) [Cleaved into: 
Botulinum neurotoxin G light chain; 






























Botulinum neurotoxin type E 
(BoNTE) (EC 3.4.24.69) 
(Bontoxilysin-E) [Cleaved into: 
Botulinum neurotoxin E light chain; 





























Botulinum neurotoxin type B 
(BoNTB) (EC 3.4.24.69) 
(Bontoxilysin-B) [Cleaved into: 
Botulinum neurotoxin B light chain; 




























Botulinum neurotoxin type D 
(BoNTD) (EC 3.4.24.69) 
(Bontoxilysin-D) [Cleaved into: 
Botulinum neurotoxin D light chain; 













































2.3.2.3 Multiple sequence alignment 
Multiple sequence alignment of the different BoNT serotypes was performed by Clustal
3
. 
Based on the multiple sequence alignment, the similarity between BoNT serotypes sequences 
were less than the similarity between BoNTA subtypes, as expected. The variable amino acids, 
weakly and strongly conserved residues as well as strongly conserved regions are summarized in 
the Table 2.5. The critical regions for differentiation of BoNT serotypes sequences were found 
based on the multiple alignment and ExPASy website information. The transmemberane regions 
of the BoNTA were compared to the other BoNT serotypes in Figure 2.7. The result indicates 
that the regions are not fully conserved between the different serotypes.  However, the active site 
and zinc binding residues in the different BoNT serotypes were fully conserved (Figures 2.8 and 
2.9). As shown in the Figure 2.10, the two amino acid cysteines at 430 and 1235 involved in 
disulfide bonds are fully conserved in the all different BoNT serotypes whereas the other two 
amino acid cysteines at 454 and 1280 are variable in some of the BoNT serotypes. Previously, 
three important amino acids for the protein activity were identified experimentally including 
amino acids Glu262, Phe266 and Tyr 366 (Figure 2.11). Mutagenesis of these amino acids 


















fully conserved residue 
1, 8, 9, 10,12, 13, 19, 35, 37, 39, 44, 47, 49, 86, 90, 95, 97, 99, 100, 106, 109, 118, 121, 194, 203, 229, 
230, 234, 236, 237, 238, 240,243, 245, 246, 247, 276, 280, 281, 282, 289, 307, 311, 330, 336, 337, 345, 
354, 361, 367, 379, 382, 401, 406, 408, 420, 421, 426, 447, 476, 479, 499, 522, 550, 573, 574, 577, 589, 
591, 595, 596, 615, 623, 626, 633, 634, 643, 645, 646, 649, 655, 656, 658, 660, 661, 662, 672, 675, 680, 
684, 686, 690, 694, 699, 703, 718, 720, 722, 725, 729, 733, 740, 746, 747, 755, 759, 762, 765, 770, 774, 
777, 782, 798, 805, 808, 809, 812, 817, 820, 821, 833, 837, 841, 844, 848, 855, 875, 876, 881, 887, 898, 
904, 915, 917, 919, 929, 967, 970, 971, 989, 990, 991, 992, 993, 1001, 1002, 1003, 1004, 1015, 1017, 
1021, 1031, 1033, 1042, 1044, 1046, 1050, 1051, 1052, 1053, 1054, 1062, 1063, 1064, 1065, 1067, 
1073, 1085, 1087, 1104, 1107, 1110, 1111, 1120, 1130, 1133, 1134, 1137, 1143, 1144, 1147, 1207, 







2, 11, 17, 42, 57, 63, 64, 102, 122, 125, 164, 210, 286, 287, 331, 353, 356, 413, 422, 446, 484, 486, 487, 
489, 503, 511, 569, 579, 582, 586, 590, 607, 609, 612, 613, 616, 618, 620, 621, 642, 681, 621, 746, 757, 
760, 771, 773, 780, 784, 803, 816, 832, 835, 858, 863, 883,884, 892, 893, 896, 909, 911, 827, 937, 943, 
969, 975, 980, 983, 994, 995, 1014, 1058, 1060, 1070, 1082, 1141, 1205, 1212, 1219, 1232, 1249, 1261, 








6, 14, 15, 22, 36, 43, 45, 46, 48, 60, 82, 83, 85, 87, 89, 91, 96, 98, 110, 113, 119, 130, 139, 159, 160, 
161, 168, 170, 193, 199, 209, 211, 226, 232, 262, 277, 279, 296, 304, 326, 339, 349, 350, 357, 358, 366, 
374, 376, 383, 396, 397, 405, 407, 409, 414, 439, 472, 474, 481, 492, 493, 497, 517, 518, 519, 545, 549, 
572, 576, 588, 593, 601, 605, 606, 622, 630, 631, 637, 547, 548, 550, 551, 553, 554, 557, 663, 669, 671, 
683, 685, 691, 693, 696, 701, 705, 711, 715, 717, 724, 728, 731, 735, 736, 741, 742, 744, 748, 759, 764, 
767, 775, 778, 781, 785, 790, 793, 794, 799, 801, 806, 810, 813, 818, 819, 822, 823, 825, 830, 836, 845, 
846, 851, 860, 866, 870, 874, 878, 884, 891, 903, 906, 914, 921, 923, 925, 938, 939, 941, 948, 949, 957, 
958, 959, 963, 965, 972, 973, 976, 996, 999, 1000, 1005, 1007, 1019, 1027, 1029, 1040, 1045, 1047, 
1049, 1054, 1056, 1061, 1075, 1076, 1079, 1089, 1099, 1101, 1102,1106, 1115, 1116, 1123, 1129, 1131, 
1132, 1135, 1139, 1140, 1145, 1146, 1152, 1154, 1155, 1197, 1208, 1209, 1210, 1230, 1240, 1243, 




8-10/ 12-13/ 236-238/ 245-247/ 280-282/ 336-337/ 420-421/ 573-574/ 595-596/ 633-634/ 645-646/ 655-











Figure 2.7 Multiple sequence alignment of the different BoNT serotypes. The transmemberane 











Figure 2.8 Multiple sequence alignment of the A-G BoNT serotypes. The fully conserved 
EXXX in the active site in the different BoNT serotypes is shown by an arrow. BoNT serotypes 
are as follow: Q60393: BoNTG, P10844: BoNTB, P10845: BoNTA, P30996: BoNTF, Q00496: 










Figure 2.9 Multiple sequence alignment of the A-G BoNT serotypes. The fully conserved zinc 
coordinating amino acids of the different BoNT serotypes are shown by the arrows. BoNT 
serotypes are as follow: Q60393: BoNTG, P10844: BoNTB, P10845: BoNTA, P30996: BoNTF, 











Figure 2.10 Multiple sequence alignment of the A-G BoNT serotypes. The amino acids involved 
in the disulfide bonds of the different BoNT serotypes are shown in the red boxes. BoNT 
serotypes are as follow: Q60393: BoNTG, P10844: BoNTB, P10845: BoNTA, P30996: BoNTF, 











Figure 2.11 The mutagenesis amino acids in the different BoNT serotypes are shown in the red 
boxes. These amino acids are important due to mutagenesis of them decrease (Phe 266 and Tyr 
366) or prohibit (Glu 262) BoNTs proteolytic activity. BoNT serotypes are as follow: Q60393: 
BoNTG, P10844: BoNTB, P10845: BoNTA, P30996: BoNTF, Q00496: BoNTE, P19321: 
BoNTD and Q5DW55: BoNTC. 
 
2.3.2.4 Identification of conserved motifs 
The BoNT serotypes were characterized by the zinc protease motif pattern using 
PROSITE. The results showed that BoNT serotypes belong to peptidase M27 family 
4
. The 
pattern in each of the BoNT serotypes sequence is shown in the Table 2.6. Based on the Pfam 
database, the BoNT serotypes consist of four domains including peptidase M27, transmembrane, 
N-terminal and C-terminal domains. The arrangement of the Pfam domains found in BoNTA is 
shown in the Figure 2.12A and B 
12
. Also, the information about the domains including the 
starting and ending amino acids as well as the length of the each domain in all of the BoNT 
serotypes are shown in the Table 2.7. 
To determine the conserved motifs of the different BoNT serotypes, the PRINTS database 
was searched. The identifier for all BoNT serotypes was called BONTOXILYSIN. BoNT 






The length of motif 1 and 2, 3, and 6 were 17 amino acids. The length of motif 4, and 5 were 23 
and 13, respectively. Figure 2.14 represents the location of domains and motifs in the 3D 
structure of BoNTA. 
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Figure 2.12 BoNTA was chosen to represent BoNT serotypes. BoNTA consists of four domains. 
The arrangement of the Pfam domains in (A) an overall view of BoNTA sequence and (B) within 
the protein sequence. Each color represents one specific domain. Catalytic (peptidase_M27), 
transmembrane, C-terminal and N-terminal domains are highlighted by green, red, yellow and 
blue colors, respectively. Neutral zinc metallopeptidase region signature (PATTERN) in BoNT 
sequence is shown in the red box. 
 






















Figure 2.13 BoNTs consist of six motifs which associated with the secondary structure of 
BoNTs. Motifs are shown as color boxes in the multiple sequence alignment of BoNT serotypes. 
The light blue box located in the motif 5 represents the zinc endopeptidase pattern. BoNT 
serotypes are as follow: Q60393: BoNTG, P10844: BoNTB, P10845: BoNTA, P30996: BoNTF, 



































BoNTA 2-410 (408 aa) 549-866 (317 aa) 885-1079 (194 aa) 1088-1293 (205 aa) 
BoNTB 3-418 (415 aa) 536-853 (317 aa) 872-1066 (194 aa) 1075-1291 (216 aa) 
BoNTC 3-419 (416 aa) 545-861 (316 aa) 880-1071 (191 aa) 1080-1280 (200 aa) 
BoNTD 3-419 (416 aa) 541-857 (316 aa) 879-1067 (188 aa) 1076-1276 (200 aa) 
BoNTE 2-393 (391 aa) 518-840 (322 aa) 859-1054 (195 aa) 1063-1250 (187 aa) 
BoNTF 3-410 (407 aa) 537-858 (321 aa) 877-1074 (197 aa) 1089-1274 (185 aa) 
BoNTG 3-417 (414 aa) 541-858 (317 aa) 877-1074 (197 aa) 1083-1297 (214 aa) 
 
 
Figure 2.14 The location of domains and motifs is shown in the 3D structure of BoNTA. The 
green, red, light blue and yellow colors are representing Peptidase-M27, transmembrane, N-
terminal, and C-terminal domains, respectively. In addition, red, purple, green, light blue, 
yellow, and orange colors in VDW drawing represent the motifs (1-6), respectively. Also the 
dark blue color in VDW drawing represents pattern sequence. 
 
2.3.2.5 Visualization of variable residues in BoNT serotypes 
The 3D structure of BoNTA (as a model) was visualized using the 3BTA pdb file in VMD. 
The variable regions between different serotypes of BoNT were determined using multiple 
sequence alignment. The variable residues were only visualized in the catalytic domain (Table 




(Figure 2.15). Additionally based on the BoNT serotypes alignment, all the variable residues in 
serotype A comparing to other serotypes were determined and listed in (Table 2.8). These 
residues can be key residues for selective detection of BoNTA serotype from other serotypes. In 
other words, if a ligand binds to some of these residues, this ligand can be used as a recognition 
agent to identify BoNTA from other serotypes of BoNT, because these residues are not available 
in the other serotypes at these specific locations. To achieve this aim, all the potential binding 
sites in the 3D structure of BoNTA (2NYY) were investigated computationally using the 
program YASARA (www.yasara.org). The amino acids located within 7-10 Å from the center of 
the binding regions identified by the program Pass 
22
 were determined for each of the 33 
potentials binding sites within the BoNTA structure (Table 2.9). This table was used to prioritize 
binding sites with the higher number of key residues for molecular docking (Table 2.8). The 
binding regions identified as having selectivity to BoNTA are R16, R23, R8, R30, R13, R3, R19, 
R21, and R22. The region 16 is the most selective one with 4 key residue within 7 A from the 
center of the region. The analysis of molecular docking results will thus focus on these regions, 
in order to identify subtype-specific recognition agents. 
 
 
Figure 2.15 Variable residues in the catalytic domain between BoNT serotypes. The red colors 




Table 2.8 The variable amino acids of BoNTA based on multiple sequence alignment data are 
listed in this table. 













 Number of 
Amino acid in 
the sequence 
5 Asparagine ASN Polar Isoleucine Nonpolar Except BoNTD replaced 
by Valine 
5 
56 Glutamic acid 
GLU 
Polar/- Proline Nonpolar  55 
77 Serine polar Proline nonpolar  75 
101 Tyrosine 
TYR 





Nonpolar Proline Nonpolar  123 
130 Leucine 
LEU 
nonpolar Phenylalanine nonpolar  127 
166 Alanine 
ALA 
Nonpolar Proline nonpolar Except BoNTC replaced 






Phenyl alanine Nonpolar  180 
242 Glycine 
GLY 
Nonpolar Leucine Nonpolar Except BoNTC replaced 




Polar/ + Tyrosine Polar uncharged Except BoNTF and E 












Arginine Polar/ + Except BoNTE replaced by 











Phenyl alanine Nonpolar Except BoNTD replaced 




nonpolar Lysine Polar/+ Except BoNTC replaced 




Nonpolar Leucine Nonpolar  379 
397 Proline 
PRO 








Leucine Nonpolar Except BoNTC replaced 




 Proline  Except BoNTG &B 




Nonpolar Alanine Nonpolar Except BoNTC replaced 








Except BoNTC replaced 













Isoleucine Nonpolar  503 
580 Glutamic acid 
GLU 
Polar/- Proline nonpolar Except BoNTC &D 














Valine Nonpolar  598 
622 Methionine 
MET 
nonpolar Leucine Nonpolar  602 
 




Table 2.8 continued  
 BoNTA variable residue  The amino acid Replaced in other serotypes  Comments  
Number of 
residue in the 
alignment 




Number of residue in 
the alignment 


















Nonpolar Glutamic acid Polar/- Except BoNTC &D replaced 
by Serine 
646 
670 Aspartic acid 
ASP 
Polar/- Glycine Nonpolar Except BoNTG replaced by 
Glutamic acid 
650 
671 Aspartic acid 
ASP 
Polar/- Arginine Polar/ +  651 
676 Leucine 
LEU 
Nonpolar Phenyl alanine Nonpolar  656 





Nonpolar Isoleucine Nonpolar  692 
716 Glutamine 
GLN 





Nonpolar Serine Polar uncharged Except BoNTF and E 





Nonpolar Phenylalanine Nonpolar  725 
749 Aspartic acid 
ASP 




















Polar/ + Lysine Polar/ + Except BoNTC &D replaced 
















Nonpolar Threonine Polar uncharged  857 
886 Arginine 
ARG 
Polar/ + Isoleucine Nonpolar Except BoNTD and C 












Asparagine Polar uncharged  867 
901 Threonine 
THR 





Polar/ + Glycine Nonpolar  893 
932 Aspartic acid 
ASP 





Nonpolar Phenylalanine Nonpolar  914 
944 Leucine 
LEU 
Nonpolar Serine Polar uncharged Except BoNTE 




Polar/ + Asparagine Polar uncharged Except BoNTG 






Isoleucine Nonpolar Except BoNTC &D&B 
replaced by Valine 
943 
 




Table 2.8 continued 
 BoNTA variable residue  The amino acid Replaced in 
other serotypes 
 Comments  
Number of 
residue in the 
alignment 
Name of residue Amino 
acid 
group 
Name of residue Number of residue in 
the alignment 
Name of residue Amino 
acid 
group 
1135 Aspartic acid 
ASP 
Polar/- Asparagine Polar uncharged  1103 
1155 Valine 
VAL 
Nonpolar Isoleucine Nonpolar  1123 
1169 Lysine 
LYS 
Polar/ + Arginine Polar/ + Except BoNTC 





nonpolar Tyrosine polar  1194 
1276 Leucine 
LEU 






Nonpolar Leucine Nonpolar Except BoNTC 





Table 2.9 The amino acids located within 7-10 Å from center of each 33 potential binding sites 
are summarized. The highlighted ones are important to differentiate BoNTA from the other 
serotypes. The highlighted residues are non-conserved amino acids. The yellow highlighted ones 
are still remained in the same group of amino acid while the blue highlighted ones are from 
different group of amino acid.  
 





Table 2.9 continued 
 









Table of 2.9, continued 
 
















In this study, the comparison of BoNTA subtypes sequences indicated that the sequence 
homology in the BoNTA subtypes is relatively high (%83) with fully conserved amino acids 
involved in zinc binding and disulfide bonds and highly conserved transmembrane regions. 
BoNTA-G serotypes were compared. The results showed that the similarity between the 
serotypes is above 50%. Higher residues variability was seen among the serotypes compared to 
subtypes of BoNTA, as expected. However, amino acids involving in catalytic activity and zinc 
binding are still fully conserved among the 7 serotypes. In the case of disulfide bonds, two of the 
four amino acids were fully conserved in all BoNT serotypes whereas the other two were 
variable in BoNTD and C serotypes. Although all the serotypes share the same pattern 
([G S T A L I V N ] - { P C H R } - { K N D } - H - E - [ L I V M F Y W ] - { D E H R K P } - H -
{ E K P C } - [ L I V M F Y W G S P Q ] ), the same motifs (1-6) and the same domains, the amino 
acids in those regions showed some variability between the serotypes. In addition, by exploring 
the multiple sequence alignment of the BoNT serotypes, we identified nine binding regions with 
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In this study the FRET assay was employed to identify paclitaxel as an inhibitor (IC50 of 
5.2 μM) for the catalytic domain of BoNTA. The specific binding of paclitaxel to BoNTA LC 
was confirmed using scintillation proximity assay. Preliminary confirmation of binding of Pac-
BDP (a paclitaxel fluorescent derivatives) to BoNTA LC was obtained in a FP assay. 
3.2 ABSTRACT 
We have successfully identified one new inhibitor and one new fluorescent recognition 
agent for the botulinum neurotoxin subtype A (BoNTA) using the virtual screening protocol 
Protein Scanning with Virtual Ligand Screening (PSVLS). Hit selection used an in-house 
developed Holistic Binding scoring method. Selected hits were tested experimentally for 
inhibitory activity using Fluorescence Resonance Energy Transfer (FRET) assays against the 
light chain (catalytic domain) of BoNTA. Ligand binding was determined against the light and 
heavy chain BoNTA complex either through radiolabeled ligand binding assays (non-fluorescent 
ligands) or fluorescence intensity assays (fluorescent ligands). These experimental assays have 
confirmed one compound (paclitaxel) to inhibit BoNTA's proteolytic activity experimentally 
with an IC50 of 5.2 μM. A fluorescent derivative was also confirmed to bind to the toxin, and 
therefore is a suitable candidate for the rational design of new detection agents and for the 
development of fluorescence-based multi-probe detection assays. 
 
KEYWORDS: botulinum neurotoxin subtype A, botulism, botulinum toxin inhibitors, detection 





Botulinum neurotoxin (BoNT) is considered the most poisonous toxin known 
(http://www.cdc.gov). It is extremely potent and lethal, and it is also easy to produce, transport, 
and use for weaponry.
1-2
 Inhalation or ingestion of BoNT causes a neurological syndrome 
(botulism) that can lead to death by paralysis of the breathing muscles within 24 hours.
3
 The 
toxin prevents the release of the transmitter acetylcholine (ACh) in synapses and neuromuscular 
junctions, thus impeding communication between neurons and muscle cells, which results in 
muscle paralysis.
2
 The toxin prevents release of the transmitter ACh by cleavage of specific 
soluble N-ethylmaleimide-sensitive attachment protein receptor (SNARE) through the toxin’s 
light chain (a zinc-dependent endoprotease). All seven BoNT subtypes, labeled A to G, prevent 
ACh release.
2, 4-8
 However, the specific SNARE protein and cleavage site targeted vary among 
the seven serotypes. Serotypes A, C and E cleave synaptosome-associated protein of 25 kDa 
(SNAP-25), each at a unique peptide bond. Serotype C also cleaves syntaxin. Serotypes B, D, F, 
and G target synaptobrevin (also known as vesicle-associated membrane protein). All serotypes 
require substrates with a minimum of 40 amino acids for efficient cleavage.
9
 The subtype A 
toxin is responsible for the highest mortality rate in botulism.
10
Botulinum neurotoxins are 
synthesized as inactive single chain proteins, cleaved, and released as two-chain (a 100 kDa 
heavy chain and a 50 kDa light chain) complexes. The heavy (HC) and the light chain (LC) are 
bound together by one disulfide bond (this complex is referred to throughout the text as whole 
BoNTA).  
The mechanism of action and potency of BoNT makes it an effective therapeutic agent. 
Successful treatment of over 50 conditions involving hyperactivity of nerves communicating to 






conditions range from incontinence, spasticity, and focal dystonia (sustained contraction of 
muscles), to pain. BoNT is particularly useful for managing symptoms of Parkinson’s Disease 
(PD), such as tremors, dystonias, sialorrhea (drooling), and constipation.
13-14, 18-21
 However, the 
most notorious use of BoNT is cosmetic to temporarily reduce the appearance of wrinkles. 
22
 
Under brand names such as Botox® (Allergan, Inc.) and Dysport® (MedicisPharmaceuticalCo.) 
BoNT injections have become the most performed non-surgical cosmetic procedure in the world. 
22-25
Although effective, the clinical use of BoNT is not without risk. Recent findings have shown 
that locally injected BoNT may affect unintended sites, either directly or indirectly,
26-32
 and may 
induce long-term undesirable effects.
33-34
 
BoNT's cosmetic, medical and homeland security importance 
35
 has fueled an intense 
search for small molecule inhibitors of its protease activity. Several studies 
35-43
have reported 
novel inhibitors for BoNTA which are promising drug candidates, all of them with activities in 
the micromolar range. Four small molecule inhibitors based on the 4-amino-7-chloroquinoline 
scaffold of anti-malarial drugs 
36
  were discovered using structure-based pharmacophore 
elucidation and optimization. These inhibitors were found to have IC50s from 3.2 to 17 µM 
against the botulinum neurotoxin subtype A light chain (BoNTA LC).Computer-assisted design 
of BoNTA-specific hydroxamate inhibitors led to a compound that discriminates between 
BoNTA LC and BoNTB LC.
42
 Pharmacophore search was also used to identify BoNTA LC 
inhibitors from the National Cancer Institute Open Repository (NCIOR).
37
This search led to the 
identification of compound NSC 240898 (Kd = 4.6 µM), deemed to be a promising lead for the 
development of novel therapeutics. A similar search was used to identify another inhibitor from 
the NCIOR possessing a previously unidentified scaffold, diazachrysene.
41
 This scaffold was 




coordinating inhibitor with Ki = 600  nM.
38, 41
Peptidomimetics successfully resulted in a potent 
inhibitor (Ki = 41 nM) of BoNTA LC.
43
 High-throughput screening was successful 
40
 in 
identifying two lead compounds with in vivo activity that represent previously unrecognized 
chemical scaffolds for the development of therapeutic agents to treat BoNT exposure. Out of 12 
compounds found to inhibit BoNTA LC experimentally with IC50s in the 1-95 µM range, only 6 
caused 35% or more decrease in SNAP-25 cleavage in cell-based assays. Surprisingly, only 2 of 
the 12 confirmed inhibitors showed in vivo activity.
40
 High-throughput screening combined with 
Structure-activity Relationship (SAR) studies were used to develop inhibitors containing the 
hydroxamate moiety on different scaffolds in an attempt to minimize the promiscuity for other 
proteases inherent to this metal chelator.
39




Despite all the efforts, the discovery and development of new inhibitory agents for 
therapeutic use has had limited success translating from in vitro to in vivo activity. 
40, 45-46
The 
inhibitory activity of most of these small molecule inhibitors is based on the coordination of the 
zinc cation (Zn
+2
) in the active site of the toxin, 
37, 40, 42, 46
 which is a common feature of zinc-
dependent metalloproteases. These compounds tend to lack sufficient affinity because their 
binding is mostly due to zinc coordination and not anchored to specific atomic interactions to 
amino acids within the pocket of the protein. The identification of inhibitors with a different 
mode of binding is, thus, desirable.   
In this paper, we report the successful identification of a new inhibitor and a new 
fluorescent recognition agent for BoNTA using a computer-assisted discovery methodology. 
These compounds were identified by an in-house developed methodology, Protein Scanning with 






a new in-house developed scoring function called Holistic Binding (Floriano et al., in 
preparation). The fluorescent derivative was shown experimentally to bind to BoNTA complex, 
the form in which the toxin is distributed throughout the body, and is useful for the development 
of novel detection assays for BoNTA. The inhibitor reported here represents a previously 
unidentified class of inhibitors and may lead to development of high-specificity BoNTA 
inhibitors for therapeutic use. The results presented in this study indicate that Holistic Binding is 
an efficient approach for the identification of recognition agents for BoNT. 
3.4 METHODS AND PROCEDURES 
3.4.1 Overall strategy. 
The PSVLS methodology was used to computationally screen a library of 1,624 chemical 
compounds. This virtual library was designed to include compounds readily available 




C) to facilitate experimental confirmation of lead 
candidates. Binding scores for each chemical compound (ligand) in the screening library were 
calculated using the Holistic Binding scoring function, which requires the molecular docking of 
each ligand into all available binding pockets within the target protein. Ligands were ranked by 
Holistic Binding scores and five were selected for experimental confirmation of binding. These 
included one compound predicted to be a strong inhibitor, two compounds predicted to have 
borderline affinity for the catalytic site of the toxin, one compound known to delay onset of 
botulism and predicted to have borderline affinity by Holistic Binding, and one compound 
predicted to be inactive (a “non-binder”). Selected hits were tested for binding to the target 
protein and for inhibition of catalytic activity. Ligand binding was determined using radiolabeled 
ligand binding assays, while inhibition of catalytic activity was determined using Fluorescence 




recombinant light chain of BoNTA, which is catalytically active, while binding assays used non-
activated BoNTA heavy and light chain complex. Confirmation of binding to whole BoNTA was 
important because the catalytic site is expected to be partially occluded in the whole BoNTA,
49-51
 
which may affect efficacy of the inhibitor in vivo.  Three commercially available fluorescent 
derivatives of one confirmed hit (paclitaxel) were docked computationally to whole BoNTA, and 
tested experimentally for binding to whole BoNTA using fluorescence intensity. The objective 
was to investigate whether any of these derivatives might be useful as a recognition agent in a 
detection assay. 
In addition to in-house developed software for PSVLS and Holistic Binding score 
calculations, the programs Yasara (www.yasara.org) and MOE (www.chemcomp.com) were 
used for generation and manipulation of 3D structures, and for structural analysis of docked 
complexes.  All chemical compounds were purchased from Sigma Aldrich 
(www.sigmaaldrich.com) and Cedarlane Labs (www.cedarlanelabs.com). Toxin was obtained 
from List Biological Laboratories (www.listlabs.com) and from Metabiologics 
(www.metabiologics.com). PSVLS calculations were performed on High Performance Computer 
Clusters running the Linux operating system. 
3.4.2 Computational screening 
Selection and preparation of the ligand database to be computationally screened. In order 
to facilitate the experimental validation of the PSVLS/Holistic Binding scoring methodology, we 
constructed a database of chemical compounds that are readily available for purchasing with a 
14
C or a 
3
H radioactive label. Compounds for virtual screening were selected from the Available 
Chemicals Directory (ACD) (Symyx, Inc.) through DiscoveryGate (www.discoverygate.com). 








sdf format (2D) and converted to three-dimensional (3D) structures using MOE 
(www.chemcomp.com). Ligand structures were stripped of counter-ions. Gasteiger atomic 
charges were assigned to each ligand in the database. The ligands were subject to geometry 
optimization followed by energy minimization using the Dreiding force field. 
52
 The final 
optimized 3D structures were saved as multiple-ligands in mol2 format and used for virtual 
screening. 
Preparation of the target protein for structure-based virtual screening. The experimentally-
determined 3D structure of the target protein, botulinum neurotoxin subtype A, was downloaded 
from the RCSB Protein Data Bank (www.rcsb.com). We used the structure identified by the 
PDB code 2NYY (2.6 Å resolution) which corresponds to whole BoNTA (heavy and light 
chains). The structure was checked for missing atoms and/or segments, and overall structural 
quality using the software packages Yasara (www.yasara.org) and/or MOE 
(www.chemcomp.com). Ligands, co-factors, and counter ions present in the pdb file were 
removed, and missing atoms/segments were added to the structure. Missing segments Ala490-
Glu492 and Thr623-Lys626 were copied from PDB structure 3BTA (BoNTA at 3.2 Å 
resolution). The complete structure was assigned CHARMM22 
53
 atomic charges and energy-
minimized for 2,000 steps of conjugate-gradient minimization using the Dreiding force field.
52
 
Protein Scanning with Virtual Ligand Screening (PSVLS). In this in-house developed 
approach, the 3D structure of a target protein is scanned computationally for potential binding 
sites using the program Pass.
54
 This program is one of many methods available for identification 
of binding pockets in proteins.
55-64
Pass is freely distributed, efficient, and its outputs are 
compatible with the downstream applications in PSVLS, making it a convenient choice for our 




accurately. The size, shape and burial extend of these voids are used to assess their likelihood to 
represent binding pockets. A virtual library of chemical compounds is screened against each 
available binding pocket identified by Pass within the target protein using molecular docking. 
Virtual screening is performed using the HierVLS protocol,
47
 with parameters adjusted to 
produce more accurate results at the expense of computational time. HierVLS is a computational 
protocol for fast screening of large chemical compound libraries.
47
 HierVLS uses a hierarchical 
approach: a large number of bound configurations are created in the least computationally 
expensive step for each ligand. Subsequent steps reduce the number of bound configurations per 
ligand while increasing the computational time required to process them, thus increasing 
accuracy. The last step includes the calculation of the binding energy with solvation for the best 
surviving bound configuration of each ligand. PSVLS generates 3D structures and calculates 
force field-based binding energies for each ligand bound to each binding region of the target 
protein. For each binding region, i, force field-based binding energies (FF_BE) are calculated as 
the difference between the sum of potential (PE) and solvation (SE) energies of the bound state 
minus the unbound state: 
(EQ 1)                                                            
                 
Ligands with favorable (more negative) calculated binding affinities to the target binding 
site are potentially active compounds.  
The 1,624 ligands in the virtual library were computationally screened against each one of the 
33 binding regions identified in the BoNTA structure (pdb code 2NYY) using PSVLS. This 
virtual screening generated 1,624 X 33 = 53,592 bound structures and respective calculated 




(formerly known as Cassandra)
48
 graphical user interface on a Linux-based High Performance 
Computer Cluster. The average time for each ligand docked into all 33 binding regions of the 
BoNTA structure was 35 hours on one core of a Intel Core 2 Quad core processor, and each run 
generated >200 GB of data.  
Selection of PSVLS Hits. The force-field based scores calculated in PSVLS for each ligand 
bound to a targeted site within the protein reflects the affinity of the ligand for that particular site. 
Once in close proximity of each other, however, on-target but off-site binding events may take 
place. These events are reflected in the binding constants measured experimentally but are not 
directly considered, to our knowledge, by any of the current methods for calculating binding 
affinities. In our Holistic Binding scoring approach, the binding scores for each ligand are 
calculated as a function of the force field-based binding energies calculated by PSVLS at each 
available binding pocket. The force field-based binding energies are scaled by a propensity factor 
(second term in equation (2)) that reflects the ratio between the force field-based binding energy 
for region i and the sum of the force field-based binding energies for all n regions: 
(EQ 1)                
      
∑       
 
   
 
 The result of this approach is a set of ligands ranked by binding affinity for a particular 
binding site relative to all other potential sites within the target protein.  
The results of PSVLS/Holistic Binding scoring were analyzed in order to identify potential 
inhibitors targeting the catalytic region of BoNTA. Ligands with less than 70% of their 
molecular surface buried into the binding region within the protein were eliminated from the list, 
regardless of binding energy. Overly charged ligands and ligands with phosphate groups were 
excluded from consideration to avoid bias introduced by the limitations of the force field in 




ranked according to their calculated Holistic Binding scores. Ligands with better (more negative) 
Holistic Binding scores are more likely to bind experimentally to the target protein.   
3.4.3 Experimental confirmation of selected hits 
Inhibition Assay. Catalytic activity of BoNTA was determined using fluorescence 
resonance energy transfer (FRET) in an assay that requires no separation of free from bound 
ligands. SNAPtide® (FITC/DABCYL) (List Laboratories, Inc), a synthetic quenched fluorescent 
peptide containing the native cleavage site for botulinum toxin type A, was used in competition 
assays against the ligands selected for testing. Cleavage of the substrate by BoNTA releases the 
fluorophore (FITC) and full fluorescence is restored. The increase in fluorescence intensity is 
directly proportional to the amount of cleavage that has occurred and thus allows for accurate 
measurement of enzymatic activity.  
Light chain BoNTA recombinant protein (BoNTA LC) was purchased from List 
Laboratories, Inc., and reconstituted in a buffer of 20 mM HEPES and 0.1% TWEEN-20 at pH 
8.2. Enzymatic activity was determined prior to ligand binding experiments for 10nM of BoNTA 
LC in a FRET assay using SNAPtide® unquenched calibration peptide (List Laboratoris, Inc.).  
The correlation coefficient for a linear fitting of concentration versus Relative Fluorescence 
Units (RFU) was 0.996 for a concentration range from 0.0125 µM to 0.8 µM of substrate.  
SNAPtide® substrate was reconstituted following the manufacturer's instructions. A final 
concentration of 8 µM SNAPtide® per well was used for the competition assays. Ligands were 
purchased from Sigma-Aldrich, Inc., and from Cedarlane Laboratories. These were: paclitaxel 
[CAS 33069-62-4] from Taxusbrevifolia (≥95% purity) and semi-synthetic (≥97% purity); D-(-)-
fructose [CAS 57-48-7] (≥99% purity); desmosine [CAS 10019-68-8] (99.5%±0.2% purity); 




Ligands were prepared as 1 mM stock solutions and diluted appropriately. DMSO, deionized 
water, 2.0M aqueous NaOH, or ethanol was used as solvent, according to the solubility profiles 
of each ligand. Whenever DMSO was used as solvent, its final concentration in the assay was 
kept at less than 2% of the volume, to prevent inhibition of cleavage by the solvent. Ligands 
were tested in triplicate for a fixed 10nM concentration of toxin in a volume of 250 µl per well. 
For the competition assays, substrate was added to the mixture of toxin and ligand. Assays were 
performed in 96-well black polystyrene microplates (OptiPlate, PerkinElmer, Shelton, CT, USA, 
http://las.perkinelmer.com/). FRET assays were run at 37°C after 1 hour of incubation. 
Excitation wavelength was set to 490 nm and emission was set to 523 nm, with a cutoff filter at 
495 nm. Fluorescence intensity was recorded 1 hour after mixing using a Synergy 4 microplate 
reader. The percent of inhibition caused by each ligand at each concentration tested was 
calculated relative to the fluorescence intensity measured for uninhibited cleavage of 
SNAPtide®, which was determined in triplicate for the same concentrations of substrate and 
toxin used in the competition assays.  
Dose-response curve. A dose-response curve was determined for paclitaxel using the 
FRET assay described above. A final concentration of 8 µM SNAPtide® and 10 nM of BoNTA 
LC in a total volume of 200 μl per well was used for the competition assays. Assays were 
conducted in triplicate at 37°C. Paclitaxel and toxin were incubated for 30 minutes prior to the 
addition of SNAPtide®. The DMSO effect on the assay was taken into account using controls 
with concentrations varied from 0.0008% to 40%.  EDTA (ethylenediaminetetraacetic acid) was 
used as an inhibitor control at varying concentrations (10 mM-10 pM). EDTA is known to have 






Immobilization of BoNTA to magnetic beads for separation. For assays requiring 
separation of free from bound ligands, biotinylated BoNTA (heavy and light chains) was 
immobilized onto streptavidin-coated magnetic purification beads (BcMag-streptavidin from 
Bio-Clone, Inc., www.bioclon.com). Biotinylated whole BoNTA was purchased (Metabiologics, 
Inc) as 1 µg/ml solution in standard buffer. The beads were washed three times with deionized 
water prior to toxin immobilization, and the supernatants were discharged. Magnetic beads (2 µl) 
and whole BoNTA solutions corresponding to 0.2 µg of toxin were incubated for 30 minutes at 
room temperature at pH 7.4. Loaded (toxin-attached) beads were washed with buffer (25 mM 
HEPES, 0.3 mM ZnCl2, and 0.2% TWEEN-20) to remove the excess of protein. Protein 
concentration was determined for the supernatants of the immobilization and washing steps by 
absorbance at 280 nm using 200 µl aliquots. The amount of streptavidin released from the beads 
during washing steps was estimated for aliquots without toxin. Loaded beads were re-suspended 
in buffer prior to use.  For separation, microcentrifuge tubes containing suspended beads were 
placed in a magnetic separator (Bio-Clone, Inc.) until the supernatant became clear and could be 
aspirated (2-3 minutes). For all assays, non-specific binding to the beads was determined by 
mixing ligands with beads, without toxin, under the same conditions of the assays being 
performed. Total binding was determined based on reading of the beads and supernatant 
fractions. 
Ligand Binding Fluorescence Intensity (FI) Assays. Fluorescent paclitaxel derivatives were 
tested for binding against whole BoNTA using fluorescence intensity assays. The toxin was 
attached to magnetic beads to facilitate separation. The samples containing ligand and toxin were 
read relative to reference samples of the fluorescent ligands in buffer. Buffer was used as blank. 




suspended beads and incubated for 1 hour prior to reading. Beads were separated from 
supernatant using a magnetic separator. Fluorescence intensity was determined for both 
fractions. Bead fractions were re-suspended in buffer for reading. Fluorescent derivatives of 
paclitaxel were purchased from Invitrogen, Inc.: Oregon Green 488 paclitaxel [CAS 301844-13-
3] (pac-OG); BODIPY®FL paclitaxel[CAS N/A] (pac-FL); BODIPY® 564/570 paclitaxel [CAS 
N/A] (pac-BDP). Stock solutions for the ligands were prepared according to manufacturer's 
recommendations. Ligands were tested in triplicate at 10 μM, for a fixed 10 nM concentration of 
toxin. For these assays, the whole BoNTA toxin (List Laboratories, Inc) was used. Whole 
BoNTA was reconstituted in a buffer of 20 mM HEPES, 0.3 mM ZnCl2, and 0.2% TWEEN-20 
at pH 8.2. BoNTA was not activated with DTT for this assay. The MW of whole BoNTA is 
150,000 Daltons.  Ligands and toxin were incubated in the same buffer used to reconstitute the 
toxin for 1 hour at 37˚C prior to reading. The concentration of toxin was determined by 
absorbance at 280 nm. Excitation and emission wavelengths were set according to the 
fluorophores to be tested (excitation/emission): BODIPY® FL (505nm/515nm), BODIPY® 
564/570 (565nm/571nm), and Oregon Green 488 (496nm/524nm). The BODIPY® fluorophores 
are boron dipyrromethene derivatives. BODIPY® FL is 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-
diaza-s-indacene-3-propionic acid, whereas BODIPY® 564/570 is 4,4-difluoro-5-styryl-4-bora-
3a,4a-diaza-s-indacene-3-propionic acid. Oregon Green® 488 (2',7'-difluorofluorescein) is a 
fluorescein analog. 
Radiolabeled Ligand Binding (RLB) Assays. We used radiolabeled ligands to probe 
binding of selected ligands to whole (heavy and light chains) BoNTA. Ligands found to inhibit 
catalytic activity of BoNTA LC do not necessarily bind to whole BoNTA because the catalytic 
site is believed to be inaccessible in whole BoNTA,
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 Since binding to whole BoNTA may contribute positively to in vivo activity of 
the inhibitors, we tested confirmed inhibitors for binding to the heavy and also to the light chain 
BoNTA complex.  
Radiolabeled ligands were purchased from Sigma (St. Louis, MS): D-fructose-UL-
14
C at 
1.0 mCi/ml, with specific activity of 300 mCi/mmol, and purity ≥95%, as determined using 
HPLC by the manufacturer; and Paclitaxel-(2-benzoyl-ring-UL-
14
C) at 0.25 mCi/ml, specific 
activity of 50.7 mCi/mmol, and purity of 99.9% determined using HPLC by the manufacturer. 
The assay buffer was 25 mM HEPES with 0.2% TWEEN-20 at pH 8.2. Radiolabeled ligands 
were incubated with whole BoNTA attached to magnetic beads for 1 hour at room temperature. 
D-(-)-fructose was tested at 10 µM (1.2 uCi) and paclitaxel was tested at 25 µM (0.5 uCi). The 
final assay volume was 400 µl per vial. The supernatant fraction was separated from the beads 
fraction using a magnetic separator. Aliquots of 3 ml of EconoSafe scintillation cocktail (Sigma-
Aldrich, Inc.) were added to each vial. Counting was performed using both fractions in duplicate 
samples, on a Beckman LS6500 scintillation counter. Each vial was counted for 10 minutes. This 
counting time was determined sufficient to reduce the standard deviation to less than 1% of the 
mean counts per minute. Total and free radiolabeled ligand concentrations were estimated from 
counting beads and supernatant fractions. Non-specific binding to the beads was determined as 
described earlier. 
Scintillation Proximity Assay (SPA). We used SPA to confirm the dose-dependent binding 
of paclitaxel to BoNTA LC. Streptavidin-coated Polyvinyltoluene SPA beads were purchased 
from PerkinElmer, Inc., and reconstituted in 20 mM HEPES buffer at pH 7.4, 0.1% Tween 20, 
and 0.3 mM ZnCl2. Paclitaxel [2-benzoyl ring-3H] at 1 mCi/ml, with specific activity of 60 




American Radiolabeled Chemicals, Inc. (St. Louis, MO). BoNA LC (30 µg) was biotinylated 
using ChromaLink
TM
 Biotin One-Shot Antibody Labeling Kit (Solulink, Inc).  At each ligand 
concentration, Paclitaxel [2-benzoyl ring-3H] and 7nM biotinylated BoNTA LC were incubated 
for 15 minutes at room temperature before addition of SPA beads at 2mg/ml per well. The assay 
was run in triplicate at the final volume of 200 µl per well, with readings at 1 hour intervals. 
Scintillation was counted on a MicroBeta2 plate counter (PerkinElmer, Inc) and corrected for 
non-specific binding/non-proximity effects.   
3.5 RESULTS AND DISCUSSION 
3.5.1 PSVLS/holistic binding scores. 
Results from PSVLS consist of 3D structures for each ligand bound into each binding 
cavity of the target protein, and their respective force field-based binding energies. A total of 
53,592 protein ligand complexes were generated for the 1,624 screened ligands bound to 33 
binding cavities in the BoNTA structure.  The 3D structure for BoNTA used in the PSVLS 
calculations and the location of the centers for the 33 binding cavities identified in this structure 
are shown in Figure 3.1. Some of these binding regions correspond to known binding sites for 
substrates (Catalytic Site), and for polysialogangliosides and protein receptors which bind to the 
Receptor Binding Domain. The other sites are uncharacterized and may or may not function as 
allosteric sites. They are, however, cavities large enough to accommodate the binding of a small 
organic molecule. Holistic Binding scores were calculated for each binding site of BoNTA by 
combining the force field-based energies, corrected for solvation, according to equation EQ 2. At 
each binding site targeted for docking, these scores represent the binding affinity of a ligand for 
that particular site relative to all the other sites. In this paper, we report only the analysis of the 




also obtained for other sites. The Holistic Binding scores for each one of the 1,624 ligands 
screened bound to the catalytic site of BoNTA are shown in Figure 3.2. The mean Holistic Score 
for the entire library in the catalytic site is -1.9 kcal/mol. The mean scores for the other 32 
regions ranged from -0.9 kcal/mol to -2.8 kcal/mol. 
 
Figure 3.1 Structure of botulinum neurotoxin subtype A (BoNTA) (heavy and light chains) and 
location of the centers for the 33 binding cavities targeted by PSVLS. The structure for BoNTA 
corresponds to pdb code 2NYY. Color scheme: Catalytic Domain (Light chain; residues 2-410) 
is cyan; Translocation Domain (residues 411-871) is gray; Receptor Binding Domain motif 1 
(residues 872-1087) is blue; Receptor Binding Domain motif 2 (residues 1088-1293) is green. 
Zinc in the Catalytic Site is represented as pink spheres. Yellow spheres represent the centers of 
binding regions identified and targeted for molecular docking by Protein Scanning with Virtual 
Ligand Screening (PSVLS). Some of these binding regions correspond to known binding sites 
for substrates (Catalytic Site), and for polysialogangliosides and protein receptors which bind to 
the Receptor Binding Domain. This was generated using the molecular modeling software 
Yasara (www.yasara.org). 
 
Most ligands in a random library are not expected to have specific affinity for the target 
protein. Using the binding energy definition in equation (EQ 1), these "non-binders" should 




bound state). However, non-specific intermolecular interactions with the protein may produce 
below zero scores for these "non-binders". In terms of score distribution, this means that the vast 
majority of ligands in a library will score within certain values while very few ligands, if any, 
with specificity for the protein target will produce much better scores (more negative, in the case 
of our scoring function). The threshold score that discriminates binders and non-binders can be 
estimated from the frequency distribution diagram shown in Figure 3.3. Most ligands (68%) 
scored near -2 kcal/mol. The vast majority (87.5%) scored ≥-3.0 kcal/mol and should be 
considered non-binders. If we optimistically consider that 2% or less of the library may be 
binders, then ligands with scores equal to or lower than -5 kcal/mol should be considered for 
experimental testing.  This value corresponds to the mean of binding energies (show as solid line 
in Figure 3.2) plus two times the standard deviation for the data set (shown as dashed line in 
Figure 3.2). This binder (at or below) versus non-binder (above) threshold is region-specific, and 
must be determined for each binding region of interest. It is also case-specific and may vary with 







Figure 3.2 Holistic Binding scores at the catalytic site for BoNTA complexes from PSVLS. More 
negative numbers correlate to better binding. Solid line labeled "mean" represents mean value of 
Holistic Score for the ligand library. Dashed line represents the mean plus two standard 
deviations (non-binder/binder threshold). Ligands scoring below this threshold may bind 
experimentally to the target protein. 
 
 
Figure 3.3 Frequency distribution of Holistic Binding scores at the catalytic site. Bars represent 
the percent of PSVLS complexes that fall into a score bin centered at the plotted value. The 
Holistic Binding score mean value for this compound library was -1.9 kcal/mol. 87.5% of 
ligands have scores above -1.0 kcal/mol. 9.6% of the ligands have scores of -4.0±1 kcal/mol. The 
top 2.8% have scores of -5.0 kcal/mol or better. Biologically active compounds are more likely 






3.5.2 Relative contribution of other regions to the holistic scores 
The contribution from FF binding energies in other regions to the Holistic Scores at the 
catalytic site can be summarized as follows: except for paclitaxel, all of the other ligands selected 
had 3 to 8 kcal/mol difference between the FF energy at the catalytic site and at the next best 
non-catalytic site. This translates into less than 1 kcal/mol difference in Holistic Scores. For 
paclitaxel, the catalytic region has the highest FF binding energy (-90.9 kcal/mol), followed by 
three non-catalytic regions with FF binding energies around 80 kcal/mol, which are considerably 
worse than the FF binding energy in the catalytic site. All three non-catalytic regions are at the 
interface between the catalytic and translocation domains. The differences in FF energies relative 
to the catalytic site yield Holistic Scores differences from 2.5 to 2.3 kcal/mol.  Aminopterin and 
fructose have better FF binding energies in other regions of the target protein than in the catalytic 
site, and this trend is preserved in the Holistic Scores.  
3.5.3 Selection of PSVLS hits for experimental testing 
Five ligands were selected for experimental testing (Figure 3.4). Selection was based on 
their Holistic Binding scores and ranking at the catalytic site. We chose to focus on the catalytic 
site because of the existence of a well-established experimental assay to validate the 
computational predictions about inhibitory activity.  After experimental confirmation of the 
initial 5 ligands, 3 fluorescent derivatives of the best confirmed ligand (paclitaxel) were also 
docked, scored and tested experimentally for binding. All ligands were re-ranked after inclusion 
of these fluorescent derivatives to the ranking list. The ligands selected for experimental testing 





Paclitaxel has the 6th best score in the catalytic site, and the top three (3) scores are its 
derivatives. The 4th and 5th best ranking ligands were known complexing agents for removal of 
heavy metal ions and a surfactant. They were expected to have low selectivity for BoNTA for 
reasons discussed earlier and were, therefore, not selected for experimental testing. The catalytic 
region has the highest binding affinity to paclitaxel (-11 kcal/mol), followed by three non-
catalytic regions (27, 5 and 23) with affinities between -8.5 kcal/mol and -8.7 kcal/mol, which 
are considerably worse than the binding affinity in the catalytic site. These regions contributed 
the most for the adjustment of the FF binding energy into the catalytic site holistic score. The 
score for paclitaxel in the catalytic region is well below the non-binder/binder threshold for the 
catalytic region (-5 kcal/mol) and, for this reason, we expect paclitaxel to bind strongly and 





Figure 3.4 Chemical structures of the lead compounds discovered by Protein Scanning with 
Virtual Ligand Screening (PSVLS) combined with Holistic Binding scoring. These compounds 
were tested experimentally for inhibition and/or binding to BoNTA. (a) paclitaxel; (b) 
aminopterin; (c) desmosine; (d) fructose; (e) monensin. 
 
Desmosine binds to the catalytic site of BoNTA with a score (-5.5 kcal/mol) just above our 
non-binder/binder threshold.  This compound should display some inhibitory activity 
experimentally.  
Aminopterin binds to the catalytic site of BoNTA with a score (-4.2 kcal/mol) above 




median value for the library (-1.9 kcal/mol). Hence, it is expected to exhibit low inhibitory 
activity, if any.  
Monensin, a sodium and proton selective ionophore antibiotic, is known to delay the onset 
of botulism. Two mechanisms have been suggested for Monensin’s ability to delay muscular 
paralysis: control of endosomal acidification which does not involve direct binding to the toxin, 
69
 and inhibition of toxin-induced channel formation.
70
  In our calculations, monensin was found 
to bind to the catalytic site of BoNTA with a score of -4.1 kcal/mol. This value is above (worse 
than) the binder/non-binder threshold of -5 kcal/mol, but it is much better than the median (non-
binder) value of -1.9 kcal/mol, similarly to aminopterin. We expect this compound to have low to 
no inhibitory activity. 
Fructose has a score of -1.8 kcal/mol at the catalytic site, which places this compound in 
the "non-binder" category. Hence, this compound is expected to be inactive experimentally as 
inhibitor of BoNTA catalytic activity. The best score for fructose across all binding regions is -
1.9 kcal/mol (region 17). Therefore, fructose is a good choice for negative control in the binding 
experiments targeting both whole BoNTA as well as BoNTA LC. The experimental confirmation 











Table 3.1 Holistic Binding (HB) scores and predicted activity for inhibitor candidates selected 
for experimental testing. Scores were obtained from virtual screening of the botulinum 
neurotoxin subtype A (BoNTA), heavy and light chains, against 1,624 chemical compounds. A 
discussion of the rationale used for hit selection is presented in the text. 
 






HB Predicted Activity  
Binding to BoNTA 










-11.0 6 Yes (strong) -90.9 91 
D-(-)-fructose
 
-1.8 735 No -29.1 1285 
Desmosine
 





May be (low to none) -118.6 36 
Monensin
 
-4.1 70 May be (low to none) -79.8 163 
1
Ranking based on Holistic Binding scores for the catalytic site of BoNTA. More negative scores 
are better. The threshold of binding energy used to consider a compound to be a “binder” in the 
catalytic site is -5 kcal/mol. Ligands with scores more negative than this threshold have better 
chance to bind experimentally to the target. Ranking reflects the inclusion of fluorescent 
derivatives of paclitaxel to the ranking list after paclitaxel was selected for testing and confirmed 
experimentally to bind to BoNTA. 
2
Ranking based on raw Force Field (FF) scores for the catalytic site of BoNTA, provided for 
comparison. The threshold of binding energy to consider a compound to be a “binder” in the 
catalytic site for FF-based scores is -106 kcal/mol. Among the compounds in this table, only 
aminopterin would be predicted as a "binder" by the FF-based scores. Using this scoring scheme, 
5.6% of the ranked library would have to be tested experimentally to identify paclitaxel as a 
BoNTA inhibitor. 
 
3.5.4 Inhibition of BoNTA catalytic activity by selected hits 
The results of the FRET assay against the light chain (catalytic domain) of BoNTA are 
shown in Table 3.2. These preliminary experimental assays indicated that paclitaxel inhibits the 
botulism toxin’s proteolytic activity experimentally by 95% at 10µM (semi-synthetic paclitaxel). 
Additional assays have found that paclitaxel isolated from natural sources inhibit BoNTA LC by 
85% at 10µM. A dose-response curve, shown in Figure 3.5(a), was constructed for paclitaxel 




determined the IC50 for paclitaxel to be 5.2 µM ± 1.1 µM over two independent experiments. The 
dose-response curve for EDTA (known to inhibit catalytic activity) is also shown in Figure 
3.5(a) for comparison. Paclitaxel is solubilized using DMSO as co-solvent, which was found to 
be well tolerated in the SNAPtide assay for up to 25% DMSO.
71
 Our results indicate that the 
fluorescence intensity produced by fixed concentrations of toxin and SNAPtide is stable up to 
4.8% DMSO. At higher DMSO concentrations, the effect of the solvent needs to be taken into 
account. The concentration-dependency of paclitaxel binding to BoNTA LC was confirmed by a 
dose-response curve, shown in Figure 3.5(b), constructed using the SPA assay described earlier.  
 
Table 3.2 Inhibition of BoNTA light chain catalytic activity by selected hits. 
 
Ligand % Inhibition at 10 µM
1 






Percent inhibition was calculated in FRET assays using 8 µM of SNAPtide. The concentration 
of BoNTA LC recombinant protein was 10 nM. Assays were performed at 37˚C, pH 8.2, in 
triplicate. Toxin was added to solutions of buffer, substrate and ligands. Samples were incubated 



































Figure 3.5 (a) Inhibition curve for paclitaxel and EDTA (positive control) against the FRET 
substrate SNAPtide® (8 µM). The IC50 for paclitaxel against the light chain (catalytic domain) 
of BoNTA (10 nM) was estimated to be 5.2 µM using a four-parametric nonlinear regression 
model (Prism5, GraphPad Inc.). (b) Specific binding curve for Paclitaxel [2-benzoyl ring-3H] 
against the light chain (catalytic domain) of BoNTA (7 nM) obtained in a SPA assay. Curve-
fitting was performed with a four-parametric nonlinear regression model (Prism5, GraphPad 
Inc.). These results confirm the concentration-dependency of paclitaxel binding to BoNTA LC. 
 
Paclitaxel is a marketed drug used for cancer treatment. It targets tubulin, interferes with 
the dynamic instability of microtubules and, thus, prevents cell division.
72
 The use of paclitaxel 
as a therapeutic agent for botulism is likely to be undesirable because of its insolubility and its 
toxic effects. However, paclitaxel may provide a good starting point for the rational design of 
novel inhibitors for therapeutic use. Other terpene (farnesyl pyrophosphate -5.7 kcal/mol), 
terpene precursor (geranylgeranyl pyrophosphate -5.2 kcal/mol), and taxane (docetaxel -5.8 
kcal/mol) were found to have favorable Holistic Binding scores in our calculations. Although 
they have not yet been confirmed experimentally, these compounds may provide additional 
assistance for rational design of potent BoNTA inhibitor. The finding that paclitaxel inhibits 
BoNTA may also have implications for the development of new anti-cancer treatments. Zinc 
deficiency was found to reduce paclitaxel efficacy in LNCaP prostate cancer cells.
73
 This fact 




proteases present in early-stage cancerous cells, in addition to its well-documented role as a 
disruptor of microtubule function. LNCaP cells are a model for early-stage prostate cancer and 
this additional role for paclitaxel may help in the identification of early-stage biomarkers for 
prostate cancer. The zinc-dependent effect was not observed in PC3 cell lines, which are a model 
for late-stage prostate cancer.
73
 
As predicted by the analysis of Holistic Binding scores, fructose shows no inhibitory 
activity against BoNTA. The ligands predicted to be borderline for binding showed low 
inhibitory activity. Monensin displayed 38% inhibition at 10 µM, which is better than anticipated 
and suggests that direct inhibition may be a secondary mechanism to the ones already proposed 
for this ligand’s ability to delay onset of botulism. 
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 Desmosine and aminopterin showed low 
inhibitory activity (25% and 11% at 10µM), consistent with their Holistic Scores. Both are at the 
non-binder/binder threshold. Aminopterin showed intrinsic fluorescence at 100µM with emission 
peak at 463 nm, and may interfere with fluorescence readings at high concentrations.  
The force field binding energies (FF_BE) and ranking for each one of the compounds 
discussed above is also provided in Table 3.1 for comparison. The non-binder/binder threshold 
for the catalytic region of BoNTA using FF_BE values is -106 kcal/mol. Under the FF_BE 
ranking, only aminopterin would have been considered a "binder", and the identification of 
paclitaxel would have required the experimental testing of 5.6% of the screening library. These 
results emphasize the better performance of the holistic binding scheme compared to traditional 
force field-based scoring. 
3.5.5 Paclitaxel fluorescent derivatives 
In addition to the search for novel potent inhibitors, fast and reliable detection of BoNTA 





This assay is laborious, expensive, time-consuming, and ethically controversial. Other 
technologies are available 
74-80
  but none is ideal for fast, low cost and portable devices that 
accurately detect the presence of the toxin in a variety of field, clinical and food samples. 
Existing detection technologies are based on the catalytic activity of BoNTA. However, the 
BoNTA catalytic site is believed to be occluded when the light and heavy chain are connected. 
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Since the toxin only releases its light chain under reducing conditions, the efficacy of these 
assays depends on the breakage of the disulfide bond connecting the light and heavy chains. 
Therefore, the discovery of small molecules suitable as recognition agents for BoNTA is 
desirable. 
Upon experimental confirmation of paclitaxel as an inhibitor of BoNTA, we investigated 
fluorescent derivatives of paclitaxel that could be used as recognition agents for detection of 
BoNTA. Three commercially available derivatives were tested experimentally for binding to 
whole BoNTA. They were tested against whole BoNTA because the catalytic site of BoNTA is 
believed to be partially occluded in whole BoNTA, and a good recognition agent must be able to 
detect the whole toxin. This is the form of the toxin before the catalytic domain is translocated 
with the help of the translocation domain into the cytosol, where neurotransmission is inhibited 
as a result of SNARE protein cleavage by the catalytic domain.
67
 The paclitaxel fluorescent 
derivatives were also submitted to PSVLS/Holistic Binding scoring. The intention of these 
calculations was to verify whether the Holistic Binding approach could have identified the 
experimentally positive compounds as "good binders". All three derivatives scored well (Table 
3.3), but only one of them was found to effectively bind to whole BoNTA (Table 3.3). Analysis 
of the ligand-protein interactions for the best PSVLS complex of each paclitaxel fluorescent 




buried in the binding site in the structures of pac-BDP and pac-FL but more exposed to solvent 
in the pac-OG structure. The fluorophore (BDP, FL or OG moiety) is exposed in the structure of 
pac-BDP, somewhat exposed in pac-FL and buried within the binding cavity in pac-OG. This 
fluorescence intensity assay results against whole BoNTA follow the same trend. Hydrogen 
bonds to Gln162, Lys166, Glu64 and Arg536 anchors pac-OG to the site and are likely 
responsible for a more favorable calculated binding affinity compared to pac-BDP and pac-FL. 
The ligand-protein interaction diagrams are available as supporting information. 
These fluorescent paclitaxel derivatives are used for imaging microtubule formation and 
for labeling microtubules in solution. Their direct use as BoNTA recognition agent is limited, as 
their known target (tubulin) could cause a false positive reading in the assays. However, the 
experimentally confirmed conjugate (pac-BDP) can be used as a lead for the design of highly-
specific fluorescent probes for BoNTA. This compound can also be useful in multi-probe 
fluorescence-based detection assays, where elimination of false positives can be accomplished by 













Table3.3 Binding of fluorescent recognition agent candidates against the botulinum neurotoxin 
subtype A non-activated heavy and light chain complex (whole BoNTA). Binding to the catalytic 
domain (light chain) of BoNTA and inhibition of catalytic activity does not assure binding to 
whole BoNTA, which is necessary for reliable detection. 
 





Experimental Binding Against 
Non-activated Whole BoNTA 
(%Bound Ligand) 


































Ranking based on Holistic Binding scores for the catalytic and for the best non-catalytic 
binding site of BoNTA. More negative scores are better. Derivatives were added to the ranking 
list after paclitaxel was selected for testing and confirmed experimentally to bind to BoNTA. All 
ligands were re-ranked after inclusion of paclitaxel fluorescent derivatives to the ranking list. 
3
Radiolabeled Ligand Binding. Paclitaxel and fructose were tested in duplicate at 50 µM 
(paclitaxel[14C] and fructose[14C]), 25 µM (paclitaxel[14C]) and 10 µM (fructose[14C]) for 
binding to non-activated 0.1 µg/ml whole BoNTA, at room temperature and two pHs (5.5 and 
7.4), with consistent results. Biotinylated toxin was attached to streptavidin-coated magnetic 
beads for separation of free and bound ligands. 
2
Fluorescence Intensity (FI). Fluorescent ligands were tested at 10 µM against non-activated 
0.1 µg/ml whole BoNTA. The toxin was attached to magnetic beads for separation. FI was 
measured in duplicate relative to the reference sample of each fluorescent ligand, after 1 hour 
incubation at room temperature and pH 7.4. Excitation/Emission wavelengths: Pac-FL 
(505nm/515nm); Pac-BDP (565nm/571nm); Pac-OG (496nm/524nm). 
 
3.5.6 Binding of paclitaxel to whole BoNTA 
Inhibitors unable to bind to BoNTA before the catalytic domain reaches the cytosol may be 
less effective than inhibitors that target whole BoNTA. In order to probe whether paclitaxel 
binds to whole BoNTA in addition to the exposed BoNTA LC, radiolabeled ligand binding 








complex. Fructose was used as negative control as it is not expected to bind to any form of 
BoNTA. The toxin was attached to magnetic beads for separation. Absorption at 280 nm was 
used to confirm that the beads were loaded with toxin prior to the assay.  Paclitaxel was tested at 
50 µM and 25 µM, while fructose was tested at 50 µM and 10 µM. The amount of toxin was 
kept constant. Specific binding of paclitaxel to the whole toxin was consistent at both 
concentrations (7%). Specific binding of fructose to BoNTA was 5% at 10 µM and 3% at 50 
µM. Binding to non-loaded beads (non-specific binding) was 29% (25 µM) and 23% (50 µM) for 
paclitaxel, and 3% for fructose at both concentrations. The low solubility of paclitaxel in water is 
likely responsible for this relatively high non-specific binding. These results (Table 3.3) indicate 
that paclitaxel does not bind to whole BoNTA, even though it inhibits the catalytic activity of the 
toxin as confirmed by the FRET assay. However, further tests are necessary to eliminate the 
possibility that the immobilization of the toxin prevented the binding of paclitaxel by making its 
binding site less accessible. In addition, full biochemical characterization of this previously 
unidentified inhibitor is necessary to assess its potential as therapeutic agent for botulism. 
3.6 CONCLUSION 
We used the Holistic Binding computer-assisted approach to successfully identify a 
previously unknown inhibitor of BoNTA catalytic activity, paclitaxel. We showed 
experimentally that paclitaxel binds (SPA assay) and inhibits (FRET assay) BoNTA light chain 
but does not bind to whole BoNTA (radiolabeled ligand binding assay), while its fluorescent 
derivative pac-BDP binds to the heavy and light chain BoNTA complex (fluorescence intensity 
assay).  
The predictions from Holistic Binding are consistent with experimental observations, 




BoNTA. The concept of non-binder/binder thresholds determined by the mean and standard 
deviation values for the virtual library was shown to be an effective way to select hits for 
experimental testing in the case of BoNTA. Further evaluation of false positive and false 
negative rates is needed to adequately determine its predictive power. Nonetheless, we expect 
that non-binder/binder thresholds will be useful in the context of other virtual screening 
approaches as well. 
The success rate of a VLS run largely depends on the size and diversity of the chemical 
library,
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 and on the fortuitous presence of true binders (positives). In general, more is better and 
the screening of large libraries has a better chance to yield true binders. Our screening of a small 
library may seem to have been more successful than one could have expected. However, based 
on reported success rates for first-tier High Throughput Screening (0.2% to 1.91%), 
65, 82-83
 a 
library of the size we virtually screened might have 3-31 positive compounds. The ability to 
enrich the top of a ranked list with whatever true binders are present in the library is the main 
challenge of VLS. The HierVLS method used at the core of PSVLS was shown to yield good 
enrichment factors. 
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 Our present results, albeit not conclusive, indicate that the Holistic Binding 
approach is efficient at concentrating true binders at the top of the ranked list. 
The Holistic Binding approach is a time- and cost-efficient alternative to other discovery 
approaches, such as HTS. For example, a recent HTS
65
of 16,544 compounds found 34 BoNTA 
inhibitors in the first-tier screening (0.2% hit rate), which were reduced to 9 inhibitors upon a 
confirmatory ELISA assay (0.05% hit rate). The best inhibitor in this group showed 95% 
inhibition of the toxin in a FRET assay with 50nM BoNTA and 5µM SNAPTide® substrate. In 
contrast, our virtual screening of a library ten times smaller readily identified an inhibitor with 




ligands in the libraries being (experimentally or computationally) screened is certainly a 
determinant of success, our methodology was shown to be effective at identifying active ligands 
at a more accessible cost. VLS generally requires expensive High Performance Computer 
Clusters (HPCCs). However, the recent availability of service-based cloud computing 
environments such as Amazon Elastic Compute Cloud (EC2) (aws.amazon.com/ec2/) is expected 
to make virtual screening more affordable.     
The need for novel fluorescent recognition agents for BoNTA is reinforced by the recent 
development of a multi-wavelength spatial LED illumination based detector that utilizes 
SNAPtide® as probe.
84
 The detector technology for a fluorescent platform is already in place, 
but its applicability is curtailed by the limitations associated to the available probes. Although 
reliable, SNAPTide® only works if the catalytic domain of the toxin is activated and fully 
available for binding.  The development of small-molecule probes capable of working in a wide 
range of conditions is, thus, desirable and will have immediate application. Within this goal, pac-
BDP is currently being used by our group as a lead compound for the structure-based design of 
new chemical entities with improved affinity and selectivity for BoNTA. The existence of an 
experimentally determined structure for paclitaxel-tubulin (pdb codes 2HXF, 2HXH and 1IA0) 
along with our predicted ligand-BoNTA structure enables the rational design of analogs with 
reduced affinity for tubulin and increased affinity for BoNTA. The same strategy is being 
applied for the design of novel BoNTA inhibitors based on paclitaxel. 
3.7 ASSOCIATED CONTENT 
Supporting information. The following data are provided as supplementary material in a 
single pdf file: 2D ligand-protein interaction diagrams for (a) paclitaxel, (b) pac-BDP, (c) pac-




screening library docked to each of 33 binding sites in the target protein, and force field and 
Holistic Scores for the best conformer per ligand found to be in the catalytic site of the target 
protein. This material is available free of charge at http://pubs.acs.org. 
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In this study we identified two new fluorescent recognition probes (6-AFLU and APM-
BDP) for BoNTA using computer-assisted drug design. The binding of 6-AFLU to BoNTA HC 
and APM-BDP to BoNTA LC enable their simultaneous use in a multi-probes fluorescence-
based assay.  The specific binding affinity of the identified fluorescent recognition probes were 
identified using FP assay. The previous identified recognition probe (PAC-BDP) exhibited 
binding interaction to both BoNTA HC and LC. Testing both PAC-BDP and APM-BDP against 
BoNTA LC using FP indicates that their simultaneous use in a multi-probe assay is feasible. 
4.2 ABSTRACT 
Botulinum neurotoxin (BoNTA) is one of the most dangerous toxins. The oral lethality 
dose of BoNTA is estimated to be 10 µg/kg for humans. To be effective, treatment of botulism 
must start as soon as possible after exposure. Current clinical confirmation of botulism utilizes 
the mouse lethality assay, which is laborious and time-consuming. The development of a rapid, 
simple and accurate assay to detect the botulinum neurotoxin in a variety of samples may 
facilitate diagnostic confirmation, reducing the starting time of botulism treatment, and may be 
useful in food safety preventing exposure through contaminated food products. In this study, 
computational and fluorescence polarization (FP) techniques were employed to successfully 
identify two new fluorescent recognition agents for BoNTA. Along with a previously identified 
fluorescent recognition agent, these compounds enable the development of a multi-probe 
detection assay for BoNTA. Our experimental results indicate that these three ligands bind to 
spatially distinct regions within the whole BoNTA structure, supporting simultaneous use. The 
development of a multi-probe FP-based assay to identify BoNTA enables detection of the toxin 




addition, the FP format is suitable for high throughput implementation, enabling large-scale 
sample processing and may also facilitate the identification of novel inhibitors through 
biochemical screening of chemical libraries. 
4.3 INTRODUCTION 
Botulinum neurotoxin (BoNT) is produced by a gram positive bacterium, clostridium 
botulinum. There are seven serotypes of BoNT:  A, B, C, D, E, F, and G
1
. The botulinum 
neurotoxin serotype A (BoNTA) is the most potent serotype and the causative agent of botulism, 
a severe neurological paralysis that affects humans. BoNT is also a potential bioterrorism 
weapon
1-2
.  In recent years, therapeutic applications of BoNT became very attractive
3
. BoNT has 
been utilized for treatment of pain and a variety of neuromuscular and skeletal disabilities
4
. 
BoNTA is secreted as a single polypeptide molecule with the molecular weight of 150 kDa
5
. 
BoNTA consists of three functional domains: catalytic, ligand binding and translocation 
domains. The catalytic domain belongs to BoNTA’s light chain (BoNTA LC), whereas the 
translocation and the ligand binding domains are part of the BoNTA heavy chain (BoNTA HC).  
BoNTs enter the human body by ingestion or inhalation of contaminated food and aerosol, or 
through wounds. BoNTA is classified as a zinc endopeptidase protein and the active site of the 
protein is located in BoNTA LC (catalytic domain). BoNT binds to nerve cells through its ligand 
binding domain. Upon binding to the cell surface, the binding domain transfers the catalytic 
domain to the cytoplasm of nerve cell
2
. The catalytic domain (BoNTA LC) with the zinc 
endopeptidase activity cleaves SNARE (soluble NSF-attachment protein receptor) proteins. As 
consequence, the dysfunctional SNARE proteins are not capable of completing the exocytosis 
process. The disruption of cell exocytosis process consequently blocks the secretion of acetyl 






Equine Antitoxin and BoNT vaccine are the only treatments available for botulism
7
. 
However these treatments are only effective before the entrance of BoNT into the cytoplasm of 
nerve cells
7
. Therefore, early diagnostic is essential for effective treatment of botulism. Several 
in-vitro techniques have been developed for BoNT detection including cell-based assays, PCR, 
immuno-PCR
8
, lateral flow assay
9
, ELISA and mouse lethality assay (MLA). Currently, MLA is 
the only accurate assay to detect all the serotypes of BoNT. However, this technique is expensive 
(required an animal facility and specialized staff), complex, time consuming, and ethically 
questionable
2, 10
. The sensitivity of MLA was reported to be 10 pg/ml
5
. Hence, developing a fast, 
sensitive, simple, and low-cost assay to detect BoNT is very desirable. This assay should also be 
suitable for high throughput screening to allow for large-scale processing of samples and to 
enable biochemical screening for novel therapeutic agents. Also desirable is an assay format that 
is suitable for portable devices. Identification of such an assay has practical applications in food 
safety, botulism diagnostic, defense, and research involving the medical use of BoNTA. 
We chose fluorescence polarization (FP) as assay platform. FP is a powerful technique 
with applications in biophysical, drug discovery, analytical and clinical chemistry. Additionally, 
FP assay has been used for exploring protein-protein, protein-DNA and protein-ligand 
interactions
11
. The high sensitivity, flexibility and homogenous format of the FP method makes it 
an efficient technique to study protein-ligand interactions. FP is a fast and relatively cheap 
technique compare to MLA, and it is suitable for high throughput screening
11b, 12
. The principle 
behind FP is the Brownian motion theory which states that the rotation of molecules in solution 
will depend only on the size of molecules if the temperature and viscosity of the solvent remain 
constant 
13
. Thus, large molecules rotate slower than the smaller molecules in solution. During an 




measured in both vertical and horizontal directions to determine its degree of polarization. If the 
small fluorescent molecule is bound to the large protein, the emission will be more polarized 
compared to the free fluorescent molecule
11b, 14
. Several fluorescence based studies have been 
developed based on the protease activity of BoNTA. Due the fact that catalytic site of BoNTA is 
conserved through all the serotype, the lack of selectivity is the main disadvantage of relying on 
the catalytic activity of BoNTA. Additionally, fluorescent assays that depend on the toxin 
protease activity are not suitable to detect BoNTA in the early stage of contamination, when both 
HC and LC are still attached and the catalytic site in the LC is partially occluded by the HC. 
In this study, we focused on other available binding pockets within the BoNTA structure 
for identification of novel fluorescent recognition agents
15
. We used virtual ligand screening 
(VLS) to identify recognition agent candidates for BoNTA detection. This approach enabled us 
to screen a chemical database of 1,153 compounds rapidly to identify a set of compounds which 
are predicted to bind against spatially distinct sites within the target protein. The initial library 
contained primary amines suitable for fluorescence labeling with amine reactive dyes. The 
virtual screening of this library identified aspartame (APM) and 6-aminofluorescein (6-AFLU) 
as potential recognition agents. The primary amine library was computationally labeled with a 
bodipy dye that is commercially available in amine-reactive form. The virtual screening of this 
fluorescence-labeled library indicated that a bodipy (BDP) conjugate of APM would also bind to 
the target. The conjugate was synthesized and tested experimentally for binding to BoNTA LC 
and BoNTA HC separately. 6-AFLU, an intrinsically fluorescent compound, was also tested for 
binding to both BoNTA LC and BoNTA HC. Our results confirmed the binding of APM, 6-
AFLU and APM-BDP to BoNTA. Moreover, our results suggest that APM-BDP and 6-AFLU 




fluorescent recognition agent we previously identified 
16
, enable the development of a FP-based, 
multi-probe assay for BoNTA detection.  
4.4 METHODS AND PROCEDURES 
4.4.1 Overall Strategy 
A library of 1,153 primary amines (Primary Amine Database or PAD) was screened 
computationally using structure-based and ligand-based pharmacophores in order to identify 
recognition agents targeting the catalytic site of BoNTA. PAD was also computationally docked 
against BoNTA using the Protein Scanning with Virtual Ligand Screening (PSVLS) approach 
16
. 
The ligand-protein docked structures from PSVLS were scored and ranked using the original 
force field scores and the holistic binding scores 
6
. Compounds with scores lower than a 
threshold of one standard deviation below the mean score for the entire library were predicted to 
bind to BoNTA. Among those, aspartame (APM) and 6-aminofluorescein (6-AFLU) were 
selected as potential recognition agents and were tested experimentally. Additional criteria for 
selection of hits for experimental testing is included availability, toxicity, stability and price of 
the compound. Selected hits from this primary screen were computationally conjugated to a 
bodipy dye and the conjugates were docked to BoNTA. Selected ligands from this secondary 
screen were synthesized by conjugation of the base primary amine to an amine-reactive dye prior 
to experimental testing, except hits that were intrinsically fluorescent. Binding to BoNTA was 






Figure 4.1 Overall strategy adopted in this study. 
4.4.2 Computational Study 
4.4.2.1 Identification of regions with selectivity to BoNTA 
In order to identify probes with selectivity for BoNT serotype A, it is necessary to identify 
regions in BoNTA that differ from the other BoNT subtypes. To achieve this aim, variable 
residues were identified in a BoNTA protein sequence alignment. The amino acid sequences of 
all seven BoNT serotypes were obtained from the “UniportKB” database of the ExPASy (Export 
Protein Analysis System) proteomics server website. A multiple sequence alignment was 
constructed using Clustal X 
17
 with the BLOSUM30 substitution matrix, a gap opening penalty 
of 10, and a gap extension penalty of 0.10. The BoNT serotypes multiple sequence alignment 
was used to identify amino acids which are varied in BoNTA (critical residues) while conserved 
within the six other serotypes (serotype B, C, D, E, F and G). Special attention was given to non-
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conserved (for example, polar versus non-polar) amino acids between BoNTA and the other 
serotypes. Additionally, the amino acids located within 7-10 Å from the center of all thirty three 
potential binding sites in the 3D structure of BoNTA (2NYY) were identified and compared to 
the critical residues from the BoNT serotypes alignment. The regions with higher number of 
critical residues were considered as target binding sites to differentiate BoNTA from other 
serotypes. A total of nine out of the thirty three regions were identified in BoNTA 
16
 and were 
prioritized for targeting: 16, 23, 8, 30, 13, 3, 19, 21 and 22.  
4.4.2.2 Ligand-based and structure-based pharmacophore modeling and virtual screening 
A set of 44 compounds (training set) known to bind to BoNTA 
16
 was used to generate a 
ligand-based pharmacophore model. The ligand-based pharmacophore model was generated 
using Pharmacophore Query Editor implemented in MOE (www.chemcomp.com). Force field 
(MMFF94X) types and atomic charges were assigned for each molecule. The atomic charges 
corresponded to the force field standard charge values. The simulations were run in gas phase 
with a dielectric constant of 1. The total energy was minimized for each molecule in the training 
set. The parameters were as follows: Hamiltonian: Force field, and Gradient: 0.05. Molecular 
dynamics was carried under the following parameters: Ensemble: NVT (the temperature, volume 
and the number of particles are constant), Duration: 100 ps, the temperature in Kelvin (T): 300, 
and time setup: 0.0005 ps. Flexible alignment was run after energy minimization to identify 
shared chemical groups between these forty four ligands (training set) and the obtained 
information was applied to generate a pharmacophore using MOE. The iteration limit parameter 
was set to 100 for the flexible alignment. The resulting of alignment had strain energy (U) of 




alignment score (S) of -168.85 kcal/mol. The pharmacophore query editor (PQE) was used to 
generate the pharmacophore under the Polar-Charged-Hydrophobic (PCH) scheme. 
A structure-based pharmacophore was also generated using three protein-ligand structures 
of BoNTA generated by a previous molecular docking study
16
. These protein-ligand structures 
were 2NYY-Paclitaxel BODIPY, 2NYY- Paclitaxel and 2NYY- Monensin. 2NYY is the 
identification code for the BoNTA structure used in that study, which was obtained from the 
Protein Data Bank (www.rcsb.org). The three 2NYY-ligand structures were superposed to create 
the pharmacophore model using the PQE in MOE (www.chemcomp.com) and choosing PCH as 
the scheme for pharmacophore generations. Both pharmacophores were applied to screen the 
PAD.  
4.4.2.3 Molecular docking of unlabeled and fluorescence labeled libraries 
The primary amines in the PAD library were computationally conjugated to BODIPY® 
FL-X (3-Bodipy-propanoylaminocaproic acid, N-hydroxysuccinimide ester) to form a 
fluorescence-labeled PAD (FL-PAD). Each labeled compound was energy minimized using the 
SCF (self-consistent-field) approximation in MOE. SCF is quantum mechanical approach that 
can be used to optimize structures of small molecules. Both PAD and FL-PAD were 
computationally screened against the complete (HC + LC) BoNTA structure using the same 
procedures described in our previous study 
16
. All calculations were performed using high 
performance computer clusters available through SHARCNET (www.sharcnet.ca). The 
molecular docking parameters were the same for both libraries, except the buried surface cut-off 
which was lowered from 70% to 30% for the fluorescence-labeled library to compensate for the 




4.4.3 Experimental study 
4.4.3.1 Synthesis of aspartame-bodipy (APM-BDP) 
To a solution of 3-bodipypropanoylaminocaproic acid N-hydroxysuccinimide ester (5 mg, 
9.90 µmol) which was purchased from US Biological life sciences and aspartame (2.9 mg, 9.90 
µmol) which was purchased from LKT Laboratories Inc in dimethylformamide (DMF) (0.5 
mL) was added triethylamine (1.40 µL, 9.90 µmol) at 0 ºC. The reaction mixture was stirred at 
0 ºC for 30 min and at room temperature for overnight. After reaction, DMF was removed by 
freeze dryer and the crude product was purified by silica gel column chromatography using 
methanol: dichloromethane (1:5 v/v) as the eluent to get the pure product in quantitative yield. 
4.4.3.2 Photometric properties of the fluorescent compounds 
Absorbance, emission and excitation spectra of 6-Aaminofluorescein (6-AFLU) and APM-
BDP were obtained in the separate experiments using a Synergy 4 microplate reader. The 6-
AFLU was supplied from Sigma-Aldrich. A clear microplate (greiner) was used to determine 
absorbance spectra and black microplate (Nunc) was utilized for emission and excitation spectra. 
The absorbance spectra of 6-AFLU and APM-BDP were determined in the range of 300-700 nm. 
The maximum absorbance from these spectra was used as excitation wavelength to obtain 
emission spectra. Maximum emissions were determined and used to obtain excitation spectra. A 
xenon lamp was used to obtain the emission and excitation spectra of the fluorescent compounds. 
The sensitivity of signal was set at 70 and 50 for 6-AFLU and APM-BDP, respectively.  
4.4.3.3 Binding of fluorescent ligands to BoNTA HC and BoNTA LC 
Fluorescence polarization (FP) was employed to explore the binding interactions of two 
selected fluorescent ligands to BoNTA HC and LC in separate experiments. All the FP 




excitation and emission filters for these experiments were 485/20 nm and 528/20 nm, 
respectively. A 510 nm full size dichroic mirror from Biotek was used in these FP assays. The 
excitation range of the 510 nm mirror was 440-505 nm and the emission range was 515-640 nm. 
A tungsten lamp was used for all the FP assays. BoNTA HC and BoNTA LC were purchased 
from List Biological Laboratories Inc. and reconstituted using hydrolysis buffer (20 mM HEPES 
buffer PH: 8.0, 1% Tween 20). The final concentration of BoNTA (either HC or LC) was fixed 
at 2 nM and the concentrations of fluorescent compounds were varied from 20 pM to 30 µM 
range in these experiments. The fluorescent compounds were dissolved in organic solvents and 
then diluted using assay buffer (20 mM HEPES buffer PH: 8.0, 0.1% Tween 20, 0.3 mM ZnCl2) 
to make different concentrations. BoNTA (HC or LC) and assay buffer were added to microplate 
and incubated at 37 °C for 30 minutes prior to adding the fluorescent ligand to each sample. The 
plate was protected from light after addition of fluorescent compounds. The samples were run in 
duplicate and for each sample there was a duplicate control to measure the background signals. 
All the data was reported after deducting the background from the samples. The controls were 
exactly similar to the samples except that no BoNTA was present. The plate was read every 15 
minutes for at least 2 hours and the data was analyzed using GraphPad Prism 6 
(www.graphpad.com). To identify the range of linearity of the fluorescent compounds, a 
standard curve was run for each of them separately. 
4.4.3.4 FP competition assay against 6-AFLU binding to BoNTA HC 
In all FP competition experiments, the competitors, assay buffer and fluorescent ligand 
were added to the microplate and read at 37 °C as a reference prior to addition of BoNTA to the 
samples. The microplate was read every 15 min at 37 °C after adding BoNTA to each sample. 




found this order of adding reagents to be less complicated, more accurate and cheaper because 
each sample acts as its own reference before adding BoNTA. The 510 nm mirror, 485/20 nm 
excitation filter and 528/20 nm emission filter were used for this FP competition assay. To 
demonstrate competitive binding to BoNTA HC, we tested unlabeled ligands against 6-AFLU. 
The unlabeled ligands APM, Aminopterin (AMN) and Desmosine (DES) were tested at two 
concentrations using FP assay. Based on our previous computational study, AMN and DES 
predicted to bind to BoNTA HC and APM exhibited high score for BoNTA LC in our current 
study. We test APM, AMN and DES against 6-AFLU for BoNTA HC to confirm the 
computational prediction. AMN and DES were supplied from AXXORA company and Elastin 
Products Company Inc., respectively. The final concentration of 6-AFLU and BoNTA HC were 
fixed at 0.5 µM (EC50) and 2 nM, respectively. APM, DES and AMN were dissolved in assay 
buffer, deionized water and DMSO, respectively, and then diluted using assay buffer. The 
concentration of unlabeled ligands (APM, AMN or DES) was varied in each sample. 
4.4.3.5 FP competition assay against APM-BDP binding to BoNTA LC 
APM-BDP was used in an FP competition assay against APM, Paclitaxel (PAC) and 
Paclitaxel, Bodipy ® 564/570 conjugate (PAC-BDP) binding to BoNTA LC and BoNTA HC. 
PAC and PAC-BDP were purchased from USBiological Life Sciences and Invitrogen Life 
Technologies co., respectively. PAC and PAC-BDP were dissolved in DMSO and APM-BDP 
was reconstituted in methanol for stock solutions. Assay buffer (20 mM HEPES buffer PH: 8.0, 
0.1% Tween 20, 0.3 mM ZnCl2) was used for making all the dilutions.  The samples were run in 
triplicate at the final volume of 250 µl. The final concentrations of APM-BDP and BoNTA LC 
were constant at, respectively, 25 nM and 2 nM in all the samples. The 510 nm mirror with 




4.4.3.6 FP competition assay with both APM-BDP and PAC-BDP against BoNTA LC and 
HC 
In our previous study, we were able to confirm the binding of PAC-BDP to BoNTA 
complex 
16
, however we never tested PAC-BDP against the individual LC and HC chains of 
BoNTA. In this FP competition assay, the concentrations of APM-BDP and BoNTA LC or HC 
were fixed at 25 nM and 2 nM, respectively, and the concentration of PAC-BDP was varied in 
different samples. Based on the maximum excitation and emission wavelengths for APM-BDP 
(505/515 nm) and PAC-BDP (564/570 nm), we selected two dichroic mirrors and filters 
combinations: 510 mirror with 485/20 nm excitation and 528/20 nm emission filters, and 570 
mirror with 540/25 nm excitation and 590/35 nm emission filters. According to the Synergy 4 
microplate reader manual, the excitation and emission range of Biotek 510 mirror is 440-505 nm 
and 515-640 nm, respectively while the excitation and emission range of 570 mirror is reported 
to be 515-565 and 575-735 nm, respectively (Figure 4.2.A and B). We employed both mirrors to 
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Figure 4.2 Excitation and emission spectrum of APM-BDP and PAC-BDP are shown in both 
graphs (A and B). In graph A, the parallel lines mark the excitation and emission wavelength 
ranges of the 510 nm dichroic mirror. In graph B, the parallel lines represent the excitation and 
emission ranges of the 570 nm mirror. The blue and red lines represent the excitation and 
emission spectrum of APM-BDP. The green and orange lines correspond to the excitation and 
emission spectrum of PAC-BDP, respectively. 
 
4.5 RESULTS AND DISCUSSION 
 
4.5.1 Pharmacophore modeling 
In general, ligand-based pharmacophore modeling compares different conformations of 
ligands to construct a pharmacophore model that accounts for the binding of these ligands to the 
target protein. In this study, three common features (F1, F2, and F3) were identified between the 
molecules with 100%, 93% and 57% scoring percentages, respectively. Each feature represents a 
set of atoms with a physicochemical property that is important for binding (Figure 4.3). F1 
represents ML |Acc | Don which means in order to match to this feature a ligand conformation 
needs to have either a metal ligator (ML), a hydrogen bond acceptor (Acc), or a hydrogen bond 
donor at this position. F2 represents Aro | Don;  to match this feature a ligand conformation 




F3 feature represents Hyd| ML|Aro|Don which is matched by compounds having either a 
hydrophobic region (Hyd), a metal ligator (ML), aromatic feature (Aro), or hydrogen bond donor 
(Don) at this position. 
 
Figure 4.3 Ligand-based pharmacophore model shows the mapping of the identified features 
onto one of the compounds in the training set. ML: metal ligator, Acc: hydrogen bond acceptor, 
Aro: aromatic feature and Don Hydrogen bond donor. The pharmacophore features are shown as 
dotted circles. 
 
The structure-based pharmacophore was built with three features with 100% scoring, 
selected out of 22 features. F1 represents Hyd which corresponds to hydrophobic character. The 
F2 represents ML | Hyd | Don; in order to match this feature a ligand needs to have either a metal 
ligator (ML), a hydrophobic moiety or a hydrogen bond donor (Don) at this position. F3 
represents ML |Hyd | Acc | Don which means in order to match this feature a ligand needs to 
have either a metal ligator (ML), a hydrophobic moiety(Hyd), a hydrogen bond acceptor (Acc), 






Figure 4.4 Structure-based pharmacophore model shows the mapping of the identified features 
onto Paclitaxel BODIPY. ML: metal ligator, Acc: hydrogen bond acceptor, Hyd: hydrophobic 
feature and Don hydrogen bond donor. The pharmacophore features are shown as dotted circles. 
 
The generated pharmacophores were applied to pre-filter PAD using pharmacophore 
search option in MOE in order to identify molecules likely to bind to the catalytic site of 
BoNTA. During the pharmacophore-based virtual screening the pharmacophore model was 
matched to different conformations of the molecules in the library. The best conformation with 
the lowest RMSD (Root Means Square Deviation) of each molecule was selected. The number of 
selected hits after the screening of PAD using the ligand-based and structure-based 
pharmacophores were 1,100 and 303, respectively, out of 1,153 compounds comprising the 
PAD. Since both ligand-based and structure-based pharmacophores were constructed based on 
ligands that bind to the same binding site (active site), compounds that match these 
pharmacophores are expected to bind to the same site of BoNTA. The number of surviving 
compounds from the ligand-based pharmacophore screening indicates that this pharmacophore 




contrast, the structure-based approach reduced the library to 303 candidates. APM, a compound 
that also survived the primary screening of the PAD library (see section "4.5.2"), is among these 
compounds. A second compound, 6-AFLU, predicted to bind to BoNTA HC in the primary 
screening of the PAD library, did not pass the structure-based pharmacophore screening. These 
results are in agreement with experimental results discussed in sections 4.5.9 and 4.5.8 for APM 
and 6-AFLU. This agreement indicates that structures predicted by PSVLS, which were used for 
pharmacophore modeling, are fair representations of the key interactions between protein and 
ligand. 
4.5.2 Virtual screening of unlabeled ligands 
The results from the virtual screening of the PAD library were processed using three 
scoring schemes: the original force field-based scores reported by HierVLS
18
, holistic scores 
16
, 
and Principal Components Analysis (PCA). These scores are provided as supporting documents. 
The force field scores and the holistic scores of the screened ligands were plotted individually 
versus the number of ligands for each of the nine regions predicted to show selectivity for 
BoNTA (Appendix A). The ligands were ranked based on their scores (force field or holistic), 
and ligands with scores lower than one standard deviation of the mean for the entire library were 
considered to be potential binders of BoNTA experimentally. The ligands were ranked according 
to their force field and holistic scores at each particular binding region. The ligands were 
required to pass the threshold for at least one of the scoring schemes in order to be considered as 
potential binder.  For both force field and holistic scores lower (more negative) numbers means 
better binding affinity. As discussed before, we are interested on ligands passing the binder/non-
binder threshold at the nine binding sites with potential selectivity to BoNTA. Therefore the 




agent candidates. In addition to passing the binder/non-binder thresholds, candidates were 
selected according to parameters including commercial availability, structure, price, known 
toxicity, and chemical stability. Aspartame (APM) was one of the candidates selected for further 
analysis. This compound, which is a known artificial sweetener, had the proper structure for 
fluorescence labeling and it was readily available for purchase at research-grade purity. The 
other candidate selected for testing was 6-Aminofluorescein (6-AFLU) which is an intrinsically 
fluorescent molecule and, thus, was ready for fluorescent polarization experiments. Based on the 
holistic and force field scores, APM passes the binder/ non-binder threshold only in regions 16 
and 21. APM binds best in region 21, followed by region 16, both located in the catalytic domain 
of BoNTA. The score versus ligand graph for APM in regions 21 and 16 are shown in Figure 
4.5. 
 Based on the force field scores, 6-AFLU passed the binding thresholds in five of the 9 
binding sites considered, best scoring in region 8 which is located in the binding domain of 
BoNTA. 6-AFLU scored lower than the threshold in regions 23, 13, 19, 21 and 8 based on force 
field scores, although their holistic scores were not lower than threshold ( but very close to 
threshold) for all these regions. The holistic and force field scores for the entire screening library 




















R e g io n  1 6

























R e g io n  1 6






























R e g io n  2 1















































R e g io n  2 1
 
 
Figure 4.5 (A) holistic and (B) force field binding scores of all the ligands in the virtual library 
docked to region 16 in the BoNTA structure. (C) holistic and (D) force field binding scores of all 
the ligands in the virtual library docked to region 21 in the BoNTA structure. The solid lines in 
the graphs represent the average of binding scores of all ligands. The dotted lines mark one 
standard deviation above or below the average. The lower dotted line corresponds to the non-
binder/binder threshold. APM exhibited scores lower than one standard deviation in both scoring 
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Figure 4.6 (A) holistic and (B) force field binding scores of all the ligands in the virtual library 
docked to region 8 in the BoNTA structure. The solid lines in the graphs represent the average of 
binding scores of all ligands. The dotted lines mark one standard deviation above or below the 
average. The lower dotted line corresponds to the non-binder/binder threshold. 6- AFLU 
exhibited scores lower than one standard deviation Based on the original binding score graph (B) 
however 6-AFLU holistic scores was on the border of the binder/non-binder threshold (A). 
 
4.5.3 Virtual screening of fluorescence labeled ligands 
The molecular docking result for the fluorescence labeled library was analyzed using the 
same strategy described for the unlabeled ligands. During molecular docking, scores (force field 
and holistic) were calculated for each fluorescent ligand bound to each individual binding region 
within the structure of BoNTA. The fluorescent ligands were ranked based on each scoring 
scheme (force field or holistic) in the 9 binding regions of interest (selective for BoNTA) 
(Appendix B). According to both force-field and holistic scores, APM-BDP survived the 
binder/non-binder threshold in regions 21 and 23 which are located in BoNTA LC. The holistic 
score for APM-BDP was on the threshold line in region 21, however APM-BDP scores were 
lower than one standard deviation in region 23 (Figure 4.7) for both force field and holistic 
scores. APM thus was found to bind well in region 21 before and after fluorescence labeling. In 




survive the threshold in this region. Interestingly, APM did not pass the threshold in region 23 in 
the first molecular docking but, after labeling, the structure of APM-BDP became more suitable 
to bind to region 23 (based on both scoring schemes), with binding scores that indicate higher 
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Figure 4.7 (A) holistic and (B) force field binding scores of all the ligands in the virtual library 
docked to region 23 in the BoNTA structure. The solid lines in the graphs represent the average 
of binding scores of all ligands. The dotted lines mark one standard deviation above or below the 
average. The lower dotted line corresponds to the non-binder/binder threshold. APM-BDP 
exhibited scores lower than one standard deviation in both scoring schemes and thus passed the 
binder/non-binder threshold. 
 
4.5.4 Principal components analysis (PCA) of molecular docking results 
A third scoring scheme was used to select probe candidates for experimental testing.  
Principal Component Analysis was used to combined the original force field scores for each 
ligand docked to each of the 33 binding region in BoNTA into a orthogonal set of scores 
(principal components), each accounting for some variance of the original data. Generally, the 
first component (PC1) accounts for most of the variance and, for our purpose, is a score 




statistical program (version 2.17) was used to carry out this analysis 
19
. PCA was used to 
transform the molecular docking results into first principal component scores for both unlabeled 
and fluorescence-labeled ligands, as well as the combination of fluorescent labeled and unlabeled 
libraries. The attempt to use PCA was unsuccessful because of the low variance carried by the 
first component (% 47 and % 53.1). The PCA analysis graphs and the table of % variance 
provided in appendix C. 
4.5.5 Absorbance and fluorescence spectra for 6-AFLU 
6-AFLU was dissolved in acetone and then diluted using assay buffer. The concentration 
of acetone in the samples was less than 2%. The final concentration of 6-AFLU was at 20 µM in 
the samples. The absorbance spectrum of 6-AFLU is shown in Figure 4.8.A. Based on this 
spectrum, the maximum absorbance was determined to be 490 nm. The maximum absorbance 
(490 nm) was used as the excitation wavelength to obtain the emission spectrum (Figure 4.8.B), 
and the maximum emission obtained from this spectrum was applied to determine the excitation 
spectrum of 6-AFLU (Figure 4.8.B). According to these spectra, the maximum excitation and 










4.5.6 Absorbance and fluorescence spectra for APM-BDP 
The absorbance, excitation and emission spectrum of APM-BDP was determined using the 
same procedure described for 6-AFLU. Methanol was used as a solvent for APM-BDP and the 
samples were diluted using assay buffer. The concentration of methanol in the samples was less 
than 2%. The final concentration of APM-BDP was 20 µM. The maximum absorbance of APM-
BDP was obtained at 505 nm according to the spectrum presented in Figure 4.9.A. In addition, 
the excitation and emission spectra for APM-BDP, displayed in Figure 4.9.B, yield maximum 
excitation and emission wavelengths of 505 nm and 513 nm, respectively.  
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Figure 4.9 Absorbance spectrum (A) and excitation and emission spectra (B) for APM-BDP. 
 
4.5.7 Analysis of the LC/MS and NMR data of APM-BDP 
The NMR and LC-MS analytical methods were used for verification and characterization 
of APM-BDP (Appendix D). 
1
H NMR (500 MHz, CD3OD) δ 1.16-1.22 (m, 2H), 1.34-1.40 (m, 
2H), 1.42-1.51 (m, 2H), 2.08 (t, J = 7.2 Hz, 2H), 2.17 (s, 3H), 2.41 (s, 3H), 2.46-2.54 (m, 3H), 
2.61-2.69 (m, 1H), 2.87-2.94 (m, 1H), 2.98-3.08 (m, 3H), 3.12 (t, J = 7.2 Hz, 2H), 3.58 (s 3H), 
4.55 (dd, J = 5.8, 7.7 Hz, 1H), 4.62 (dd, J = 5.8, 7.7 Hz, 1H), 6.11 (s, 1H), 6.21 (d, J = 4.2 Hz, 






4.5.8 Binding of 6-AFLU against BoNTA HC and BoNTA LC 
Preliminary binding tests were run to optimize the concentration of BoNTA in the FP 
binding assay, and the final concentration of 2 nM was selected for further testing. A binding 
curve obtained by FP for 6-AFLU against BoNTA HC (Figure 4.10.A) demonstrates dose-
dependent increase in FP value which results from the specific binding interactions between 6-
AFLU and BoNTA HC. A three parameters non-linear regression (log (agonist) versus response) 
in GraphPad Prism 6 (www.graphpad.com) was used to fit the dose response curve and estimate 
EC50. The calculated EC50 of 6-AFLU against BoNTA HC was 546 ± 60nM. Based on our 
experiments, BoNTA and ligands reach equilibrium after 60 min so all the data provided in this 
study are for readings after 60 min. 
Binding of 6-AFLU was tested using FP against BoNTA LC at four concentrations (100 
pM, 100 nM, 1 µM and 50 µM) as shown in Figure 4.10.B. However, no significant difference 
between samples with BoNTA LC and samples without BoNTA LC was observed. Additionally 
the FP was dependent on the concentration of 6-AFLU, with FP decreasing due to increase in the 
number of unbound fluorescent molecules in each sample. According to the computational 
results the best score of 6-AFLU was at region 8, located in binding domain of BoNTA (BoNTA 
HC). Thus, the experimental results are in agreement with PSVLS prediction that 6-AFLUbinds 
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Figure 4.10 (A) 6-AFLU and BoNTA HC binding curve with an EC50 of 546±60nM using FP 
assay. (B) 6-AFLU tested for binding against BoNTA LC shows no significant interaction to 
BoNTA LC. The background signals were subtracted from each sample before calculating the 
fluorescence polarization. The graphs are based on two separate experiments. The concentration 
of BoNTA HC (A) and BoNTA LC (B) were fixed at 2 nM. Samples were run in duplicate in 
both assays. Binding assays were conducted at body temperature (37°C) with an incubation 
period of 30 minutes. 
 
4.5.9 Binding curve of APM-BDP against BoNTA LC 
A binding curve obtained by FP for APM-BDP against BoNTA HC (Figure 4.11.B) 
demonstrates dose-dependent increase in FP value which results from the specific binding 
interactions between APM-BDP and BoNTA LC. A three parameters non-linear regression (log 
(agonist) versus response in GraphPad Prism 6 (www.graphpad.com) was used to fit the dose 
response curve and estimate EC50. The calculated EC50 of APM-BDP for BoNTA LC was 20.96 
± 10 nM. 
 Binding of APM-BDP was tested using FP against BoNTA HC at four concentrations 
(100 pM, 1 nM, 100 nM and 1 µM) as shown in Figure 4.11.A. However, no significant 
difference between samples with BoNTA HC and samples without BoNTA HC was observed 




decreasing due to increase in the number of unbound fluorescent molecules in each sample. Thus 
we conclude that APM-BDP binds to BoNTA LC with an EC50 of 21 nM, but it does not bind to 
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Figure 4.11 (A) APM-BDP tested for binding against BoNTA HC shows no significant 
interaction to BoNTA HC (B) APM-BDP and BoNTA LC binding curve with an EC50 of 20.96 ± 
10 nM using FP assay. The background signals were subtracted from each sample before 
calculating the fluorescence polarization. The graphs are based on two separate experiments. The 
concentration of BoNTA HC (A) and BoNTA LC (B) were fixed at 2 nM. Samples were run in 
duplicate in both assays. Binding assays were conducted at body temperature (37 °C) with an 
incubation period of 30 minutes. 
 
4.5.10 FP competition assays against 6-AFLU binding to BoNTA HC 
APM, DES, and AMN were tested in competition with 6-AFLU against BoNTA HC to 
confirm our computational prediction of binding affinity of DES and AMN for BoNTA HC and 
no interaction of APM against BoNTA HC (Figure 4.12). To account for the effect of solvent in 
the FP measurement, a control was prepared for each individual sample. The concentration of 
solvent in the control was similar to its related sample. In other words, all controls contain only 




FP (maximum signal). However there are slight differences between the controls (chess pattern 
bars in Figure 4.12) which are due to the concentration of different solvents. The FP values were 
calculated after subtracting the references (the samples were read before adding BoNTA HC). 
The black bar samples contained 6-AFLU, unlabeled ligand and BoNTA HC. As evident in 
Figure 4.12 the FP signal was not changed in the presence of APM at the concentrations of 100 
and 1 µM. It means APM did not show binding interaction to BoNTA HC and no sign of 
competition between APM and 6-AFLU was observed. This result was predictable considering 
the negative result of APM-BDP binding study against BoNTA HC (Figure 4.11.A). In addition, 
the data showed that the FP signals were decreased in the presence of AMN (black bars) 
compare to the sample with only 6-AFLU and BoNTA HC (chess pattern bars). Furthermore, the 
FP signal reduction (sample with AMN) was dose-dependent. This outcome was explained that 
6-AFLU and AMN were binding to the same binding site of the BoNTA HC. The FP signal was 
reduced because if the two ligands compete to the same region, in the presence of AMN some of 
the 6-AFLU molecules were replaced by AMN molecules therefore the number bond 6-AFLU 
molecules (fluorescent molecule)were reduced and subsequently, the FP was decreased by 
increasing the AMN concentration. In the FP competition assay of DES and 6-AFLU, The FP 
responses were increased in the presence of DES (black bars) compare to the sample without 
DES (chess pattern bars) and the higher concentration of DES was shown the higher FP signal. 
This result can be explained if DES and 6-AFLU bind to two different binding regions of 
BoNTA HC. In this case the size of the complex molecule (6-AFLU-BoNTA HC-DES) was 
increased and this was explained having FP signal higher than expected maximum FP signal. In 
the other study, we were able to identify the binding interaction of radiolabeled AMN and DES 




confirmed each other. The white bar correspond to the sample which was contained only 6-
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Figure 4.12 FP competition assay against 6-AFLU binding to BoNTA HC for APM, AMN, and 
DES BoNTA HC. Each unlabeled ligand was tested at two different concentrations. In this 
graph, black bars represent FP in presence of a competitor (6-AFLU + unlabeled ligand + 
BoNTA HC) and chess pattern bars represent the FP resulting from the fluorescent agent binding 
to the protein (6-AFLU + BoNTA HC). The two values were compared to each other to 
determine the effect of the unlabeled ligands. The white bar represents the baseline signal as it 
contains only 6-AFLU and no competitor or toxin. APM did not affect the FP associated to 6-
AFLU binding to BoNTA HC and, therefore, we conclude that APM does not bind to BoNTA 
HC. AMN and DES both change the FP response. AMN decreases FP, indicating competition 
with 6-AFLU for the same binding site in BoNTA HC. DES increases FP, indicating that DES 
and 6-AFLU bind to the different binding sites in BoNTA HC. FP is dose-dependent in both 
cases, indicating specific binding. A 510 nm dichroic mirror with 485/20 nm excitation and 
528/20 nm emission filters were used for this FP competition assay. The error bars in the graph 
represent standard deviations and the stars indicate significant differences of FP signal in the 
samples with and without BoNTA HC according to two way Anova analysis. 
 
4.5.11 FP competition assay of APM-BDP for BoNTA LC 
The Figure 4.13 displays the results of competition assays for APM-BDP, PAC and PAC-
BDP against BoNTA LC. In this graph, black bars represent samples containing APM-BDP, 




BoNTA LC with no competitor. The uninhibited FP signals (chess pattern bars) for all the 
samples related to PAC and PAC-BDP (dissolved in DMSO) were almost the same. However FP 
was higher for samples related to APM which were dissolved in assay buffer (chess pattern 
signals). As previously discussed, the solvents used to solubilize the competitors had an effect on 
the ligand binding interaction and subsequently on the FP signals. The only difference between 
all the chess pattern bars samples is the presence of the solvents of competitor at the same 
concentrations of their related black bar. The white bar in this graph (Figure 4.13) shows the FP 
signal of APM-BDP alone at the concentration of 25 nM, which was fixed in the competition 
assays. By comparing the signal of each black bar to its corresponding chess pattern bar we 
concluded that all competitors APM, PAC and PAC-BDP bind to BoNTA LC. APM competes 
with APM-BDP for the same binding region of BoNTA LC as evident from the FP signal 
reduction in the presence of APM (competitor in black bars). PAC and PAC-BDP bind to 
different binding sites of BoNTA LC causing the FP signal induced by PAC-BDP to increase in 
the presence of the competitor PAC. In addition, the FP responses were dose-dependent in all 
three cases. The binding of PAC-BDP to BoNTA complex and the IC50 of PAC against BoNTA 
LC (5.2 µM) were determined in our previous paper using FP and FRET assays, respectively 
16
. 
The computational results indicated that APM-BDP should not bind to the active site of BoNTA 
LC. The experimental results confirm our computational prediction, the FP signal increases in 
the presence of APM-BDP and PAC (inhibitor for the catalytic activity of BoNTA LC) which 
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Figure 4.13 FP competition assay against APM-BDP binding to BoNTA LC for APM, PAC, and 
PAC-BDP. Each unlabeled ligand was tested at two or three different concentrations. In this 
graph, black bars (APM-BDP + Competitor + BoNTA LC) and chess pattern bars (APM-BDP + 
BoNTA LC) were compared to each other to determine the effect of competitors. The white bar 
represents the baseline signal as it contains only APM-BDP and no competitor or toxin. APM 
was decreased the FP associated to APM-BDP binding to BoNTA LC and, therefore, we 
conclude that APM binds to the same binding site of BoNTA LC. PAC and PAC-BDP both 
enhance the FP response, indicating that PAC and PAC-BDP bind to the different binding sites 
in BoNTA LC. FP dose-dependent in both cases, is indicating specific binding. A 510 nm 
dichroic mirror with 485/20 nm excitation and 528/20 nm emission filters were used for this FP 
competition assay. The error bars in the graph represent standard deviations and the stars indicate 
significant differences of FP signal in the samples with and without BoNTA LC according to two 
way Anova analysis. 
 
4.5.12 FP competition assay of APM-BDP and PAC-BDP for BoNTA LC and HC 
using two mirror sets 
In our previous study, we were able to confirm the binding of PAC-BDP to BoNTA 
complex, however we never tested PAC-BDP against BoNTA LC and HC separately. In this FP 
competition assay, the concentration of APM-BDP and BoNTA (LC or HC) were fixed at 25 and 
2 nm, respectively, and the concentration of PAC-BDP was varied in different samples. Based on 




(564/570 nm), two mirror and filters sets were selected to conduct FP competition assays: 510 
nm mirror with 485/20 nm excitation and 528/20 nm emission filters, and 570 nm mirror with 
540/25 nm excitation and 590/35 nm emission filters.  
Results obtained with the 510 nm mirror set are shown in Figure 4.14. This figure exhibits 
competition assay results for APM-BDP and PAC-BDP against BoNTA LC (A) and BoNTA HC 
(B). The data indicates that the FP signal was higher in presence of both fluorescent compounds 
(PAC-BDP and APM-BDP) compared to the samples with only one fluorescent compound 
(PAC-BDP). Clearly, this effect confirms the binding of both APM-BDP and PAC-BDP to 
different binding sites of BoNTA LC. Moreover, since the concentration of APM-BDP was 
constant in all samples, the decrease in FP observed in samples with lower concentrations of 
PAC-BDP confirms the synergistic binding. In samples with only PAC-BDP (stripe pattern 
bars), FP was also concentration-dependent. The FP of the samples with only APM-BDP (at 
constant concentration, dotted pattern) is slightly different due to the effect of solvent. The 
concentration of solvent in each dotted pattern bar are exactly the same as its related black bar. 
Additionally, FP associated to PAC-BDP and APM-BDP without BoNTA LC was determined as 
baseline of the FP readings (white column). The data was normalized before plotting. In the case 
of BoNTA HC (Figure 4.14.A), FPs were not significantly changed for the samples with (black 
bars) and without APM-BDP (stripe pattern bars). This result indicates that there is no binding 
between APM-BDP and BoNTA HC at the concentrations tested. Additionally, FP associated to 
APM-BDP binding to BoNTA HC (dotted pattern bars) are lower than the baseline (white 
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Figure 4.14 Competition assays between APM-BDP and PAC-BDP against BoNTA HC (A) and 
BoNTA LC (B). In both experiments, the concentrations of APM-BDP and BoNTA (HC or LC) 
were fixed and the concentration of PAC-BDP was varied. The black bars represent the sample 
with both fluorescent compounds and BoNTA. Striped pattern bars correspond to the mixture of 
PAC-BDP and BoNTA. The dotted pattern columns represent FP associated to APM-BDP bound 
to BoNTA (HC or LC).  The white bar represents the baseline FP corresponding to only APM-
BDP or PAC-BDP. The 510 mirror, 485/20 excitation filter and 528/20 emission filter were used 
for the both FP competition assays. 
 
The FP competition assay between APM-BDP and PAC-BDP against BoNTA LC and 
BoNTA HC were also ran using the 570 nm mirror set (Figure 4.15) due to the lack of 
availability of proper set of mirror and filter to detect both fluorophores signal at the same time. 
Additionally the competition assay using the 570 nm mirror was ran to reconfirm the results 
obtained with the 510 nm mirror (Figure 4.15). The FP measurement for samples with only 
APM-BDP and BoNTA (HC or LC) were equal to the negative control (assay buffer). This 
means that using the 570 nm mirror set we were only able to measure FP from a PAC-BDP point 
of view. However, the size of the complex should increase if APM-BDP and PAC-BDP bind at 
the same time to BoNTA LC. This explains the differences between black and stripe bars (Figure 




+PAC-BDP + BoNTA LC) at the concentrations of 1 µM and 25 nM show higher FP compared 
to their related stripe bars (PAC-BDP + BoNTA LC). This result supports that APM-BDP and 
PAC-BDP bind to the BoNTA LC. The graph A of Figure 4.15 shows that there are no 
significant differences of FP in the presence (black bars) or absence (stripe pattern bars) of 
APM-BDP which also confirm that APM-BDP does not bind to the BoNTA HC. According to 
Figure 4.15.A and B, the FP signals were decreased by reduction of the concentration of PAC-
BDP at 1 µM and 25 nM. Curiously, the FP signals at 100 nM did not follow a dose-dependent 
behavior and this singularity is seen in both experiments. Table 4.1 summarized the biological 
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Figure 4.15 Competition assays of APM-BDP and PAC-BDP against (A) BoNTA HC and (B) 
LC using 570 mirror set. In both experiments the concentrations of APM-BDP (25 nM) and 
BoNTA (HC or LC) (2 nM) were fixed and the concentration of PAC-BDP was varied. The 
black bars represent the sample with both fluorescent compounds and BoNTA. The stripe pattern 
bars correspond to the mixture of PAC-BDP and BoNTA. The white bar represents the baseline 
FP corresponding to only APM-BDP and PAC-BDP (no toxin). The 570 nm mirror, 540/25 nm 
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1.6 ± 0.3 µM 
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703 ± 98 nM 
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Enough amount of PAC-BDP was not available at the time when the experiment was carried 
out. 
2
Radiolabeled APM was not available commercially to determine the EC50 of APM using 
scintillation assay. 
3 
The EC50 obtained from other study presented in chapter 5. 
 
There are many examples in the literature of ligand binding studies that employ fluorescent 




(Depolarization After Resonance Energy Transfer) techniques were developed to detect BoNT 
serotypes in different studies 
15, 20
.  Recently, FP was used as a high throughput screening assay 
to identify coumestrol as an inhibitor for the estrogen receptors
21
. In another study the novel 
rhomboid inhibitors were identified by employing an FP assay
22
. A new antagonist was 
identified for A(2A) adenosine receptors using FP assay 
23
. The FP assay format has some 
advantages compared to other assay platforms, including the simplicity of sample preparation 
(mix and read) and the high sensitivity of the assay. Additionally, FP does not require any 
washing or separating steps which make the assay faster. The FP samples can be miniaturized to 
lower volumes which save material, and also enable large-scale testing in a high throughput 
screening assay
24
. The fluorescent conjugate probes APM-BDP and 6-AFLU both exhibit EC50’s 
in the nanomolar range against BoNTA LC and HC, respectively. The binding affinity of APM-
BDP to BoNTA LC was confirmed in the FP specific binding curve. Moreover, the FP 
competition result of APM-BDP, PAC, APM and PAC-BDP against BoNTA LC supported the 
specific binding interaction of APM-BDP to BoNTA LC. The binding curve for 6-AFLU, and 
the FP competition results of 6-AFLU, DES, AMN, PAC-BDP, and APM against BoNTA HC 
verified the binding of 6-AFLU to BoNTA HC. The FP competition results for PAC-BDP and 
APM-BDP confirm that PAC-BDP binds to BoNTA HC and BoNTA LC, while APM-BDP 
showed affinity only to BoNTA LC. These results were confirmed in two individual FP assays 
using two distinct sets of mirror and filters.  
6-AFLU is also known as a fluoresceinamine isomer II. The use of fluoresceinamine 
isomer II in biochemical assays has not been recently reported. However the isomer I (5-
aminofluorescein) was utilized in a variety of research studies for labeling peptides and fatty 
acids to characterize them by a fluorescence-based assay 
25




aminofluorescein-albumin has been used as a biomarker in brain tumor surgery 
26
. APM is a non-
saccharide sweetener produced by coupling L-Aspartic acid and L-phenylalanine. APM was 




Our results indicate that computational screening is an effective method for identifying 
recognition agents that bind to spatially distinct site within a target protein. We used a 
combination of computational and experimental methodologies to identify 6-AFLU and APM-
BDP as BoNTA fluorescent recognition agents. 6-AFLU exhibited binding affinity to BoNTA 
HC whereas APM-BDP showed binding to the catalytic domain located in the BoNTA LC. 
Binding of fluorescent probes to different locations within the BoNTA structure makes these 
recognition agent candidates suitable for use in a multi-probes fluorescent polarization assay to 
detect BoNTA. PAC-BDP, identified in our previous study as a potential recognition agent for 
BoNTA,
16
 and APM-BDP were tested in a competition assay against BoNTA LC, confirming 
that they bind to different binding site within BoNTA LC. This FP assay also confirmed that 
using multiple probes to detect BoNTA (complex structure) is feasible.  
Many studies have been conducted to identify adequate antitoxin for BoNT. However the 
antitoxins must be available in the body at the initial phase before the entrance of toxin to the 
nerve cell. The development of a homogeneous, fast, simple and reliable technique to detect 
BoNT is necessary, since early diagnostic of botulism is essential for effective treatment 
7
. 
Additionally, such assay should be suitable for high throughput screening to facilitate large-scale 
implementation in case of bioterrorism 
5
. In this study we were able to successfully identify two 
novel fluorescent recognition agents for BoNTA using PSVLS and FP techniques. A multi-probe 




agents bind to different binding sites of the BoNTA complex (HC + LC). The development of a 
multi-probe FP assay for BoNTA complex can become an effective method to diagnose botulism 
by detecting the presence of the toxin in body samples at early stage. Such assay would also have 
application in food safety, to detect the presence of the toxin in contaminated food. The active 
site of BoNTA complex is not accessible for targeting before cleavage of the toxin (activation) 
into BoNTA LC and BoNTA HC. Therefore the multi-probes FP assay can be an adequate 
method since these recognition probes targeting the other binding sites (not active site) of 
BoNTA. The FP assay was found to be rapid, relatively uncomplicated and cheaper to operate 
compare to the MLA, which is currently the only standard available to detect BoNTA. The 
detection limit of MLA reported to be 0.01 ng/ml
10
. Based on the result provided in this study, 
the FP technique was capable of detecting BoNTA LC and BoNTA HC at the concentration of 2 
nM, corresponding to 100 and 102 ng/ml, respectively. Although the minimum concentration of 
BoNT for FP detection obtained in this study is higher than the MLA detection limit, the results 
are based on individual BoNTA LC or HC. Thus, the sensitivity of the assay needs to be 
investigated using BoNTA complex. Additionally, lower concentrations (˂ 100 ng/ml) of 
BoNTA LC, HC and complex have to be tested for determination of FP threshold. 
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light chain; BoNTA HC, botulinum neurotoxin serotype A heavy chain; 6-AFLU, 6-
aminofluorescein; APM, aspartame; DES, desmosine; AMN, aminopterin; PAC, paclitaxel; 
APM-BDP, aspartame bodipy; PAC-BDP, paclitaxel bodipy; FP, fluorescence polarization; 
DMSO, dimethyl sulfoxide;  LC/MS, liquid chromatography-mass spectrometry; NMR, nuclear 
magnetic resonance; PCA, principal component analysis;  MOE, molecular operating 
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In this study, we further analyzed the computational results reported in chapter 3 in order 
to identify non-orthosteric molecular probes for BoNTA. The specific binding of Desmosine (1.6 
± 0.3µM) and Aminopterin (703 ± 98 nM) to BoNTA LC was determined using scintillation 
proximity assay. Solanesyl pyrophosphate exhibited binding affinity to both BoNTA HC and LC. 
These recognition probes were selected to target the non-conserved regions in BoNTA and may 
show selectivity for BoNTA over the other subtypes. 
5.2 ABSTRACT 
We previously reported the use of Protein Scanning with Virtual Ligand Screening 
(PSVLS) to identify a novel inhibitor and a recognition agent (molecular probe) against the 
catalytic site of the botulinum neurotoxin subtype A. In the present work, we further analyze the 
PSVLS data to identify molecular probes with affinity for binding regions other than the catalytic 
site of BoNTA. We refer to these as non-orthosteric molecular probes. Such probes can take 
advantage of unique characteristics within the structure of target proteins that discriminate them 
from other closely related proteins. Molecular probes targeting binding sites that are unique to 
the serotype of interest are expected to be less likely to bind to other serotypes, making a 
detection assay developed with such probes less prone to false positives. BoNTA is a large 
protein with a light (LC) and a heavy (HC) chain that can be assayed separately. The catalytic 
site is located in the LC. We selected for experimental testing 3 probe candidates predicted 
computationally to have affinity for different non-orthosteric binding regions within the HC and 
LC. One compound predicted not to have affinity for either domain was also selected for testing. 
Two previously tested compounds were used as positive and negative controls. The selected 




the LC or the HC of BoNTA using scintillation proximity assay (SPA). The binding profiles 
obtained experimentally confirmed that our computational methodology can successfully 
identify probe candidates targeting multiple and spatially distinct binding pocket within the 
target protein. Non-orthostheric ligands provide new opportunities for controlling the function of 
BoNTA without direct catalytic inhibition. They may also serve as subtype-specific molecular 
probes that take opportunity of unique binding pockets in BoNTA compared to other subtypes or 
other homologous proteins (potential confounders in a detection assay). Moreover, our 
previously reported inhibition assay results for these probe candidates indicate that PSVLS can 
identify probe candidates targeting binding sites that do not significantly interfere with the 
catalytic activity of the target protein. The identification of non-interfering probes opens up new 
opportunities for molecular imaging probe discovery and development. Non-interfering 
molecular imaging probes can be used for monitoring novel disease therapies without the risk of 
skewing the results with effects attributed to the probe itself. 
 
KEYWORDS: molecular probes, radiolabeled probes, non-orthosteric binding, binding to 
alternative sites in proteins, detection agents, botulinum neurotoxin subtype A, virtual screening, 
holistic binding scoring function, drug discovery. 
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A primary (orthosteric) ligand binds to the orthosteric site of its cognate protein to induce 
or suppress response. Traditionally drug discovery have targeted orthosteric sites in proteins as a 
way to control their activity. However, this approach fails to produce ligands with enough 
subtype specificity because of the high degree of conservation generally associated to 
functionally active sites. Since subtype specificity is important for many pharmacologically 
relevant targets such as G protein coupled receptors, alternative approaches have been sought. 
Recently, structure-based drug discovery efforts have shifted towards the targeting of allosteric 
sites as a way to bypass the high degree of conservation of functional sites among protein 
subtypes and closely related homologs
1
. Allosteric sites are spatially distinct from the orthosteric 
site. Binding of a ligand to an allosteric site induces conformational changes that affect the 
binding of the orthosteric ligand and/or the response of the target protein. Allosteric sites are still 
functional sites in the sense that they modulate the primary function of the protein. However they 
are under less evolutionary pressure to be conserved than orthosteric sites and hence their appeal 
as target sites for subtype specificity. Conceptually, other binding pockets within a protein may 
exist that are large enough to accommodate a ligand without producing a significant change in 
the activity associated to an orthosteric site. Such sites may provide unique characteristics that 
allow the discrimination of a protein from other closely related proteins. This type of 
discrimination is especially important in the context of target-specific molecular probes (TS-
MPs), which are recognition agents that detect a biomolecule of interest. TS-MPs are usually 
obtained by labeling a known ligand with a radioisotope or a fluorophore. Because they are 
based on known ligands, TS-MPs usually interfere with the function of the protein they are 




they are often plagued by the same specificity problems their originating ligand may have. In the 
context of TS-MPs, the possibility of finding specific probes for non-interfering/non-orthosteric 
sites is very attractive and may represent a shift in the current paradigm of probe discovery. A 
number of key questions, however, remain to be answered: would ligands targeting these sites 
have enough specific affinity for the target protein to enable their use as molecular probes? 
Wouldn't the binding of any ligand, anywhere within a protein alter its response to an orthosteric 
ligand? In order to gain insights into these questions, we targeted non-orthosteric sites in the 
botulinum neurotoxin subtype A structure for the identification of molecular probe candidates.  
Botulinum neurotoxin (BoNT),  one of the most known lethal toxins and a causative agent 
of botulism disease, is produced by the  bacterium Clostridium botulinum
2
. Botulism is a serious 
disease which affects the peripheral nerve system by cleavage of a group of proteins (SNARE). 
These proteins are involved in membrane fusion and their cleavage consequently inhibits 
acetylcholine secretion resulting in respiratory muscles paralysis and ultimately death 
3
. There 
are seven types of BoNT classified by the letters A - G and BoNTA is known as the most potent 
one 
4
. BoNT is a polypeptide molecule with a molecular weight of 150 KD. Activated BoNT is 
cleaved in two smaller chains, a heavy (HC) and a light chain (LC) with molecular weights of 
100 and 50 KD, respectively. The active site of BoNT with zinc-endopeptidase activity is located 
in the LC (catalytic domain) whereas the HC contains the binding domain of BoNT 
4-5
. BoNTA 
and B have been used as a drug since 2008 
6
. In recent years, several studies have attempted to 
identify new inhibitors of BoNT due to its various applications in different areas such as medical, 
pharmaceutical, cosmetic and the potential threat of using BoNT as a biological weapon 
6-7
. 
However, most of these studies focused on identification of novel recognition agents and 






successfully identifying a novel inhibitor and a fluorescent recognition agent. In that work, a 
library consisting of 1624 compounds including commercially available radiolabeled ligands was 
computationally screened against BoNTA. The PSVLS (Protein Scanning with Virtual Ligands 
Screening) method was used for the virtual screening. In the PSVLS method, the binding affinity 
of each ligand for every individual binding site available in BoNTA is calculated and then 
ligands are ranked based on their holistic scores 
8
. The holistic scores take into account the 
binding affinity of the ligand for all the other regions relative to the binding region of interest (in 
that paper, the catalytic site). The outcome of the PSVLS/holistic binding scoring was evaluated 
to determine novel inhibitors for BoNTA’s catalytic site.  
Here we report the analysis of the PSVLS results in Dadgar et al., 2013 
8
 for all 33 binding 
regions explored by PSVLS, with the intent of identifying non-orthosteric ligands for BoNTA. 
Non-orthostheric ligands may serve as subtype-specific molecular probes that take opportunity 
of unique binding pockets in BoNTA compared to other subtypes or other homologous proteins 
(potential confounders in a detection assay). They also provide new opportunities for controlling 
the function of BoNTA without direct catalytic inhibition. We selected four ligands based on 
their PSVLS binding profiles. Our previously identified inhibitor, paclitaxel, was used as 
positive control. D-fructose, predicted to be a non-binder by PSVLS which was confirmed in our 
previous work, was used as negative control. Selected ligands were tested against BoNTA HC 




H] aminopterin and [
3
H] 
desmosine exhibited binding interactions to BoNTA HC however considering the error bars no 
significant interactions observed against BoNTA LC. [
3
H] solanesol showed no binding affinity 
for both BoNTA LC and HC however [
3
H] solanesyl pyrophosphate exhibited high binding 




binding scoring approach is an accurate and reliable method to identify molecular probe 
candidates targeting orthosteric and non-orthosteric sites in BoNTA.  
 
5.4 METHODS AND PROCEDURES 
5.4.1 Protein Scanning with Virtual Ligand Screening (PSVLS). 
This method was used in our previous work 
8
 to screen a virtual library of 1,624 ligands 
against BoNTA in order to identify new inhibitors and molecular probes targeting the catalytic 
site of BoNTA, a metalloprotease. The results of that screening for all 33 binding sites of 
BoNTA are being further analyzed in the present work with the intent of identifying non-
orthosteric ligands for BoNTA. PSVLS is a computational protocol for virtual screening that 
targets multiple sites within the 3-dimensional (3D) structure of the target protein. PSVLS takes 
the 3D structures of a target protein and of a library of chemical compounds, scans the protein 
for potential binding sites and screens the virtual ligand library for chemical compounds with 
high affinity for any of the potential binding sites 
9
. The core computational methodology used in 
PSVLS is HierVLS
9a
, a multi-step hierarchical protocol for virtual ligand screening. HierVLS is 
a computational protocol for fast screening of large (> 500,000) chemical compounds library 
9a
. 
HierVLS uses a hierarchical approach: a large number of bound protein-ligand configurations are 
created in the least computationally expensive step for each ligand. Subsequent steps reduce the 
number of bound configurations per ligand while increasing the computational time required to 
process them (for increased accuracy). The last step is the calculation of the binding energy 
including solvation for the best surviving bound configuration of each ligand. Binding energies 
are calculated using a force field-based scoring function. For PSVLS, we apply HierVLS not 




for detection of the protein or as alternative sites for controlling biological activity. These 
alternative binding sites are identified as enclosed empty volumes large enough to accommodate 
small molecules. PSVLS provides binding affinities and bound structures for each ligand in the 
screening library, in each one of the potential binding sites in the target protein. The centers of 
the 33 binding sites identified in BoNTA (pdb code 2NYY) are shown in Figure 5.1 as solid 
spheres, with the HC and LC domains of BoNTA labeled. 
 
Figure 5.1 Molecular surface of BoNTA (pdb code 2NYY) with the centers of each of 33 
binding regions represented as spheres. The light chain (LC) and heavy chain (HC) domains 





5.4.2 Selection of Probe candidates for experimental testing 
Principal component analysis (PCA) was used to identify ligands likely to bind 
experimentally to BoNTA. This approach takes into account the affinity of the probe candidate 
for the target protein as a whole. PCA is used to reduce the binding energies across all regions 
into a single predictive score for each chemical compound screened. The first principal 
component (PC1), which has the largest variance, represents the ligands' overall affinity for the 
protein. A non-binder/binder threshold is set as one standard deviation below the mean value 
(zero for the transformed data) of the entire screening library. The underlying assumption is that 
the screening of a random library will mostly produce scores that represent non-specific 
interactions between the ligands and the protein, with only a small number of compounds 
displaying "true" binding interactions and thus passing the threshold. Ligands with a PC1 score 
passing the non-binder/binder threshold are further analyzed in terms of their individual holistic 
scores
8
 at each binding region. This allows for the selection of ligands that preferentially bind to 
specific sites within the protein. Practical aspects such as commercial availability with a tritium 
label, price, safety, and easy handling are also considered in the selection of ligands for 
experimental testing among the ones passing the binder/non-binder criteria.  
5.4.3 Materials for experiments 
BoNTA LC and HC were purchased from List Biological laboratories,inc. Radioligands 
were obtained from American Radiolabeled Chemicals Inc., except [
3
H] aminopterin which was 












solanesyl pyrophosphate (IPA:NH4OH:H2O)and [
3
H] fructose-D(Ethanol) were 38.4 Ci/mmol, 




contained 20 mM HEPES buffer at pH 7.4, 0.1% Tween 20, 0.3 mM ZnCl2, andwas used to 
prepare the dilutions of radioligands. The ChromaLink
TM
Biotin One-Shot Antibody Labeling kit 
was purchased from Solulink and used to biotinylated BoNTA LC and BoNTA HC. The 
hydrolysis buffer contained 20 mM HEPES buffer at pH 7.4 and 1%. Tween 20, and was used to 
make dilutions of BoNTA HC and BoNTA LC. Streptavidin coated PolyVinyltoluene (PVT) 
scintillation proximity assay (SPA) beads were supplied from PerkinElmer, Inc. 
5.4.3.1 Biotinylation of BoNTA HC and BoNTA LC 
BoNTA LC (30 µg) and BoNTA HC (50 µg) were biotinylated using the ChromaLink
TM 
Biotin One-Shot Antibody Labeling Kit according to Solulink’s instruction. To determine the 
concentration of the proteins, we needed two parameters including the mass extinction 
coefficient (E1%) for BoNTA/HC and LC and also their absorbance at 280 nm. The E1% of 
BoNTA/HC was reported to be 17.1 by Weatherly, G. T. et al 
10
. E1% value of BoNTA/LC was 
not available in literature. According to the extinction coefficient technical guide which exists on 
the Thermo scientific website, if the E1% of any protein is not available, then E1% equals 10 can 
be used as a rough estimation value for the protein. The biotin molar substitution ratio of 
biotinylated BoNTA LC and biotinylated BoNTA HC was calculated to be 2 and 4.3, 
respectively, using the MSR calculator of Solulink. The total biotin-labeled BoNTA LC 
recovered after biotinylation was 28.3 µg and the total labeled BoNTA HC was equal to 43.9 µg.  
5.4.3.2 Scintillation proximity assay 
The order of adding reagents was optimized in the assay as described below. Radioligand 
and protein (BoNTA LC or HC) were incubated for 30 minutes at room temperature to pre-
equilibrate before the addition of SPA beads to decrease the chance of non-specific binding. The 




ºC. SPA beads working solutions at 5 mg/ml were prepared on the day of each experiment. The 
concentration of SPA beads and biotinylated BoNTA HC (or BoNTA LC) were fixed in all 
samples at 2 mg/ml and 17 nM (or 10 nM), respectively.  All the experiments were done in 96 
well, white and flat bottom Wallac microplates and each sample was run in duplicate at room 
temperature. Scintillation was counted using a MicroBeta
2
 plate counter. To obtain comparable 
data from different runs, a correction for the radioactive half-life was applied automatically by 
the MicroBeta
2
 plate counter.  
The scintillation proximity assay was performed to measure the binding of five different 
radioligands to BoNTA HC (or LC). [
3
H] paclitaxel was used as a positive control at 50 nM 
concentration and [
3
H] fructose was used as a negative control at the concentration of 3 µM. 
These concentrations were chosen based on our previous experiments 
8
. Non-specific binding of 
radioligands to the beads was determined in the absence of BoNTA. Specific binding was 
calculated by subtracting non-specific binding from total binding. Similarly, the binding 







H] solanesol, and [
3
H] solanesyl pyrophosphate were initially tested at the concentrations of 1 





H] desmosine were assayed at two lower concentrations (250 nM and 50 nM) for binding 
to BoNTA HC in a separate assay. 
Assay format optimization. To develop the SPA for BoNTA, all three formats of adding reagents 
were tested including: coupling SPA beads and BoNTA before adding Radioligands, adding all 
three reagents at the same time, and incubating BoNTA with radioligand before the addition of 
SPA beads. Based on our study, the most suitable format of the SPA for BoNTA is delayed 




Chromophore absorbance correction. According to the emission spectrum of SPA beads (PVT) 
provided in the Amersham SPA product guide, the SPA beads (PVT) emit between 360-490 nm. 
ChromaLink
TM 
(used in biotinylation of BoNTA LC and HC) has a chromophore with maximum 
absorbance at 354 nm, which overlaps the emission spectrum of SPA beads (PVT). This means 
that part of the SPA beads’ emitted light may be absorbed by the Chromalink bound to BoNTA. 
This overlapping explains the high number of controls compared to the samples which was 
observed in our initial experiments. In this study, the only factor that was different between the 
control and the sample was the availability of BoNTA in the sample and each sample was 
compared to its control. To eliminate the effects of the Chromalink, the same amount of 
Chromalink should be available in each particular sample and its control. According to the data 
determined after biotinylation of BoNTA HC and LC, the ratio of biotin-Chromalink to BoNTA 
in labeled BoNTA LC and HC are known so the same concentration of Chromalink was added 
for the controls.   
Spa beads optimization. The ratio of protein and SPA beads is one of the critical factors in the 
SPA to obtain a maximum signal-noise ratio.  In this experiment, the concentration of SPA beads 
was variable between 0.5 - 2.5 mg/ml while the concentrations of BoNTA HC and [
3
H] 
Aminopterin were fixed at 17 nM and 1 µM, respectively. The final volume of each sample was 
200 µl and the samples were counted at the speed of 1 well/min. The final concentration of 2 
mg/ml of SPA beads was used in our Study since high separation between total binding and non-





5.4.3.3 [3H] Paclitaxel binding curve  
The effective concentration (EC50) of [
3
H] paclitaxel against BoNTA LC was determined 
using SPA assay in our previous study. The concentration of BoNTA LC and SPA beads were 




H] paclitaxel concentration was varied from 
160- 1nMin this assay. 
5.4.3.4 [3H] Aminopterin binding curve  
SPA was used to determine the effective concentration (EC50) of [
3
H] aminopterin against 
BoNTA HC at 17 nM, with SPA beads at 2 mg/ml, at room temperature. The concentration of 
[
3
H] aminopterin varied from 50 nM to 1 µM. Assay buffer was used to dilute [
3
H] aminopterin 
for this assay. The assay ran in duplicate at a final volume of 200 μl and the microplate was 
counted for 8 hours. The data was analyzed using Prism 6 (GraphPad, Inc). 
5.4.3.5 [3H] Desmosine binding curve 
SPA was used to determine the EC50 of [
3
H] desmosine against BONTA HC. The 
concentrations of BoNTA HC and SPA beads were kept constant at 17 nM and 2 mg/ml, 
respectively, while the concentration of [
3
H] desmosine varied from 10 nM to 4 µM. The [
3
H] 
desmosine dilutions were prepared using assay buffer. The samples were counted for 18 hours, 
but the specific binding remained constant after 10 hours. 
 
5.5 RESULTS AND DISCUSSION 
5.5.1 Selection of probe candidates for experimental testing 
PCA was applied to the PSVLS results in Dadgar and co-authors (2013) to reduce the force 
field scores of each ligand bound to each of the 33 binding regions identified in the structure of 




binder/binder threshold (Figure 5.2) are expected to bind experimentally to BoNTA, and were 
further analyzed in terms of their individual holistic scores at each binding region. The objective 
of the PCA was to identify ligands with strong overall affinity for BoNTA to increase the 
chances of finding true positive compounds. The objective of the per-region analysis was to 
identify ligands preferentially binding to spatially distinct regions of BoNTA belonging to each 
of the two domains, HC and LC. These domains are structurally stable and functional as separate 
units, and can be assayed independently of each other. The PSVLS-predicted binding profiles 
can thus be tested experimentally.  
 
Figure 5.2 PC1 scores for a library of 1,624 compounds computationally screened against 
BoNTA whole structure (HC and LC). Dashed lines mark one standard deviation above/below 
the mean score for the library. Ligands selected for experimental testing are highlighted. 
 
In addition to the previously tested 
8
 paclitaxel (positive control) and fructose (negative 
control), we selected aminopterin, desmosine, and solanesyl pyrophosphate. All of these 
compounds passed the non-binder/binder threshold. The region-specific binding energies for 




desmosine), LC (paclitaxel), or both chains (solanesyl pyrophosphate). Desmosine is a rare 
amino acid produced by elastin breakdown. The release of desmosine is accelerated in patients 





. Elastin is one of the main extracellular matrix proteins which 
provide elasticity and flexibility of body tissues. In patients with pulmonary inflammation 
diseases, the elastin of lung tissue degenerated by interaction of modulators and enzymes 
released by lymphocytes, neutrophils and microphages 
13
. The degradation of elastin produces 
desmosine and isodesmosine which can be measured in body fluids as a biomarker for the 
progress of pulmonary disease
14
. Solanesyl pyrophosphate is predicted to be the strongest binder 
among the ligands selected. As expected, paclitaxel passed the PC1 non-binder/binder threshold, 
and its region-specific binding energies (Figure 5.3) indicate preferential binding to BoNTA LC, 
where the catalytic site is located. This is in agreement with previously reported inhibition assays 
which confirmed paclitaxel as an inhibitor of BoNTA
8
. Also as expected, fructose did not pass 
the non-binder/binder threshold. Solanesol, a derivative of solanesyl pyrophosphate, was selected 
for testing to contrast against its parent compound, even though solanesol's PC1 score is higher 
than the threshold (albeit lower than the average score for the library). Solanesol is extracted 
from tobacco leaves and has been used as a primary material to synthesize vitamin K and 
coenzyme Q10 [30]. Aminopterin is a known anticancer drug and has been used to treat 
leukemia
15
. The ligands selected for experimental testing are listed in Table 5.1 along with their 






Table 5.1 Name and structure of the selected ligands from PSVLS. Aminopterin, desmosine, 
paclitaxel and fructose were tested at 10 µM using FRET (Fluorescent Resonance Energy 




































































5.5.2 Optimization of BoNTA and SPA beads ratio 
Basically, in a scintillation proximity assay it is necessary to optimize the concentration of 
SPA beads for each particular protein. The optimum concentration of SPA beads in this 
particular experiment was identified as 2 mg/ml. The separation between total binding and non-
specific binding was relatively high at this concentration of SPA beads (Figure 5.4). In this 
assay, [
3
H] aminopterin and BoNTA HC were used for optimizing the concentration of SPA. 
However, the optimal concentration of SPA beads was also determined to be 2 mg/ml using a 
separate assay. The final concentrations of [
3
H] paclitaxel and BoNTA LC were constant in each 
sample at (6 nM) (10 nM), respectively. 
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Figure 5.4 Optimization of SPA beads concentration. Total binding (solid line) at 2 mg/ml 
shows a wider separation from the non-specific binding (dotted line).The total binding and non-
specific binding were measured using samples that are exactly the same composition, except for 
the presence of BoNTA, which is absent in non-specific binding samples. 
 
5.5.3 Experimental binding to BoNTA HC and LC  
Preliminary SPA was performed to investigate the binding the selected ligands against 




was tested at (2000, 250 and 50 nM) concentrations against BoNTA HC separately. Due to 
observe no interaction of aminopterin (1000 nM) and desmosine (2000 nM) to BoNTA LC, the 
lower concentrations were not tested. Solanesol was tested at (1000, 300, 50 and 10 nM) and 
Sol.P.P was tested at (600, 300, 50 and 10 nM ) for BoNTA HC. Sol and Sol.P.P also tested 
against BoNTA LC only at 600 and 300 nM, respectively. All the data provided in supporting 
information (Appendix E). A summary of these results is provided in Figure 5.5. The lowest 
positive concentration tested is provided for positive ligands, whereas the highest concentration 
tested is shown for negative ligands. [
3
H] aminopterin and [
3
H] desmosine both show high 
affinity for BoNTA HC, but very low binding to BoNTA LC. Accordingly, [
3
H] solanesyl 
pyrophosphate exhibits one of the strongest binding interactions not only to BoNTA HC but also 
to BoNTA LC. The data related to [
3
H] solanesyl pyrophosphate is shown on the right axis in 
Figure 5.5. In contrast, [
3
H] solanesol did not bind to the BoNTA HC or LC at the concentrations 
tested. [
3
H] paclitaxel, which was known to be a BoNTA inhibitor in our previous work 
8
, only 
shown binding to BoNTA LC at the concentrations tested. In addition, [
3
H] D-fructose, which 
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Figure 5.5 Specific binding of each radioligand to BoNTA HC and BoNTA LC using SPA. 
Binding of radioligands to BoNTA LC or HC are shown by solid black or square pattern, 
respectively. The dotted line separates Solanesyl pyrophosphate (Solanesyl.PP) from the other 
radio-ligands due to the fact that Solanesyl.PP is plotted on the right y-axis. The error bars in the 
graph represent standard deviations and the stars indicate the significant differences between the 
samples and negative control (fructose) according to two way Anova analysis. 
 
 
5.5.4 [3H] Paclitaxel binding curve 
The [
3
H] Paclitaxel binding curve against BoNTA LC was determined in our previous 
study showed in Figure 5.6 
8
. The EC50 of paclitaxel was estimated at 16.91 nM for BoNTA LC. 
The result provided in the graph is after deduction of non-specific binding and normalizing the 
data
8
























Figure 5.6 SPA binding curve for paclitaxel against BoNTA LC. The EC50 of [
3
H] paclitaxel 
was determined to be 16.91 nM. The concentration of [
3
H] paclitaxel varied from 160 to 1 nM, 
and the concentration of SPA beads and BoNTA LC was constant for all the duplicate samples 
and controls at 2 mg/ml and 7 nM, respectively. Non-linear regression was used to plot the curve 
and estimate EC50. The error bars correspond to standard deviations. 
 
 
5.5.5 [3H] Aminopterine binding curve 
The result of the [
3
H] aminopterin binding curve against BoNTA HC (Figure 5.7) indicated 
that the specific binding is dependent on the concentration of [
3
H] aminopterin. To determine the 
specific binding of each concentration of [
3
H] aminopterin, the non-specific binding was 
deducted from total binding and then normalized between 0-100%. All samples were present in 
duplicate. The normalized data was used to generate the dose- response curve of [
3
H] 
aminopterin against BoNTA HC. To determine the effective concentration of [
3
H] aminopterin, a 
non-linear regression model (log (agonist) vs. normalized response-variable slope) was used. The 
EC50 of [
3

























Figure 5.7 SPA binding curve for aminopterin against BoNTA HC. The EC50 of [
3
H] 
aminopterin was determined to be 703 ± 98 nM using the SPA. The [
3
H] aminopterin was used at 
variable concentrations in nM range and the concentration of SPA beads and BoNTA HC was 
constant for all the duplicate samples and controls at 2 mg/ml and 17 nM, respectively. Non-
linear regression was used to plot the curve and the error bars correspond to standard deviations. 
 
5.5.6 [3H] Desmosine binding curve 
We obtained EC50 for [
3
H] desmosine against BoNTA HC from a SPA dose-response 
curve using variable concentration of [
3
H] desmosine (Figure 5.8). The data in the graph was 
normalized between 0-100% after subtracting the background. The result demonstrated that 
increasing the concentration of [
3
H] desmosine, the specific binding increases. The calculated 
EC50 for [
3
H] desmosine against BoNTA HC is 1.6 ± 0.3 µM and. A non-linear regression model 
(log (agonist) vs. normalized response-Variable slope) was applied for estimating the EC50 of 
[
3
























Figure 5.8 SPA dose-response curve for [
3
H] desmosine against BoNTA HC. The EC50 value for 
[
3
H] desmosine was estimated at 1.6 ± 0.3 µM using non-linear regression and model (log 
(agonist) vs. normalized response -variable slope). In this experiment, the concentration of SPA 
beads and BoNTA HC were kept constant at 2 mg/ml and 17 nM, respectively. The 
concentration of [
3
H] desmosine varied from 4 µM to 10 nM. The specific binding was 
determined by subtracting the background from total binding. The error bars correspond to 
standard deviations. 
 
5.5.7 Agreement between predicted and experimental binding profiles 
 The PSVLS-predicted binding profiles along with the SPA experimental results are 
summarized in Table 5.2. Aminopterin is predicted to bind preferentially to BoNTA HC, which 
is confirmed experimentally by SPA (EC50 (BoNTA HC) = 0.7 µM). Aminopterin did not score 
well in any region in the LC, consistent with SPA results that show no binding to BoNTA LC at 
1µM and supported by previously reported inhibition assays at 10 µM
8
. Desmosine shows good 
holistic scores to both HC and LC. Binding to HC is confirmed experimentally by SPA, with an 
EC50 (BoNTA HC) of 1.6 µM. Desmosine was not found to bind to BoNTA LC in the SPA assay 
at 2 µM or lower. However, binding of desmosine to BoNTA LC is supported by the weak 
inhibition (25%) observed at 10 µM in our previous work
8




paclitaxel has a strong preference for BoNTA LC, which is confirmed by SPA with EC50 of 16.9 
nM, and by a FRET inhibition assays (IC50 = 5.2 µM)
8
. The holistic scores for solanesyl-
pyrophosphate suggest that this compound binds strongly to both BoNTA HC and LC, in 
agreement with SPA results at 0.6 µM. Fructose scores very poorly in all binding regions and has 
consistently produced a negative response in all our experiments. Solanesol did not pass the PC1 
non-binder/non-binder threshold but its best region-specific holistic score in region 6, located in 
the LC, is above the region-specific threshold. No binding was observed for solanesol at 0.3 µM 
to either BoNTA HC or LC. We were unable to test solanesol at higher concentrations or in an 
inhibition assay to confirm its status. There is a very clear agreement between predicted and 
experimentally determined binding profiles for the selected ligands, indicating that PSVLS is an 




















Table 5.2 Predicted versus experimental binding profiles for selected ligands from PSVLS. 
Lowest positive concentration refers to the lowest concentration tested that gave a positive 
response. Highest concentration tested refers to the highest concentration tested that gave a 
























R27 (-4.7) HC 
TD 
R8 (-4.8) HC 
LBD 







1000 nM 4 
 







R6 (-5.5) LC CS 
R23 (-4.9)  LC 
R10 (-4.8) HC 
TC 







2000 nM 4 
 






















R27 (-13.8) HC 
TD 
R3 (-13.4) HC 
LBD 
R7 (-13.4) HC 
TC 
R2 (-12.9) LC 















































1 Score corresponds to holistic scores (Dadgar et al., 2013) at the best region(s) among the 33 
regions scanned. Multiple regions are listed if the difference in binding energies was 1 unit or 
less. Scores not passing the per-region non-binder/binder threshold are shown in bold italic. 
2 
The 
lowest positive concentration of Sol.P.P was 600 nM for both BoNTA HC and LC 
3
Ligands were tested at higher concentration against BoNTA LC, producing a negative response; 
no lower concentrations were tested afterwards. 
4 
Positive ligands at higher concentration were 
tested against BoNTA HC at two lower concentrations (250 and 50 nM), producing negative 
responses. 
NA = not applicable 
ND = not determined 
LC = light chain, including the catalytic site among others 
HC = heavy chain 
LBD = ligand binding domain in the HC 
TD = translocation domain in the HC 






Target-specific molecular probes are organic compounds that bind to a particular protein 
(the target) and report its presence in the form of a detectable signal, such as fluorescence or 
scintillation caused by radioactivity. Molecular probes can be utilized in medical imaging to 
locate regions where the target protein is present or it is more/less abundant than normal, 
indicating a disease state. They can also be utilized in laboratory assays to identify and quantify a 
protein that is associated to a disease or condition. The current paradigm of molecular probes 
discovery is to modify existing medicinal drugs known to bind to the protein of interest. 
However, this approach has a number of disadvantages: not all medicinal drugs are suitable for 
labelling; labelling with an additional chemical group may negatively impact binding affinity for 
the target; the molecular probe may have biological activity against the target protein, precluding 
its use for monitoring the effects of novel drugs against the target; not all proteins for which a 
molecular probe is desirable have known ligands. 
We applied PSVLS to identify molecular probes targeting non-orthosteric sites within the 
structure of BoNTA. The experimental binding profile obtained for 6 compounds tested 
independently against the light chain and the heavy chain of BoNTA is in excellent agreement 
with the binding profile predicted by PSVLS for these compounds.  
Our results demonstrate that the PSVLS approach has the ability to identify probe 
candidates for multiple, spatially distinct binding regions within the structure of the target 
protein. These binding regions include orthosteric, allosteric, and other non-orthosteric sites. 
This enables the use of PSVLS for identification of probes that take advantage of unique non-
conserved sites, thus increasing selectivity. Non-orthosteric binding sites are not under the same 




opportunities for the discovery and/or design of highly selective molecular probes. Moreover, 
some of the regions target by PSVLS may not interfere upon ligand binding with the main 
functional site of the target protein. This enables the use of the PSVLS probes for monitoring 
treatment response through medical imaging without the risk of affecting the actual treatment. 
Since PSVLS does not require prior knowledge of compounds that bind to the protein target of 
interest, we anticipate that this method will be able to identify molecular imaging probes for 
newly identified protein biomarkers from genomics/proteomics studies. The only condition for 
applying PSVLS to newly identified biomarkers is the availability of an experimental structure, 
or the possibility of modeling the biomarker's structure using well-established methods for 
protein structure modeling. The early identification of molecular probes will accelerate the 
validation of novel biomarkers by enabling scientists to develop target-specific assays to conduct 
their studies. 
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6 CHAPTER SIX: GENERAL DISCUSSION 
 
Botulism is a severe neurological disease cause by the botulinum neurotoxin. The BoNTA 
is the most potent one among the 7 serotypes and it is the cause of botulism in humans. 
Paclitaxel identified as an inhibitor (IC50 equal to 5.2 µM) for the zinc protease activity of 
BoNTA LC using FRET assay. Also the specific binding of [
3
H] paclitaxel to BoNTA LC was 
verified using SPA assay. The fluorescent derivative of paclitaxel (PAC-BDP) exhibited binding 
interaction to both BoNTA LC and BoNTA HC using FP. However PAC-BDP did not compete 
with PAC for the active site. The EC50of [
3
H] DES (1.6 ± 0.3 µM) and [
3
H] AMN (703 ± 98 nM) 
against BoNTA HC were obtained using SPA. Additionally, we confirmed the binding of DES 
and AMN to BoNTA HC using FP competition assay. [
3
H] Solanesyl PP is the other radiolabeled 
compound which showed strong binding affinity to both BoNTA LC and HC using SPA assay. 
Protein sequence and structural analysis of different serotypes of BoNT (A-G) showed 
similarity and identity percentages of more than 50% and 31%, respectively. This analysis 
allowed the identification of critical binding pockets that are important to detect BoNTA from 
the other serotypes. The critical binding pockets R16, R23, R8, R30, R13, R3, R19, R21, and 
R22 were explored computationally to identify two novel fluorescent recognition agents, APM-
BDP and 6-AFLU for BoNTA detection. The binding of APM-BDP to BoNTA LC and 6-AFLU 
to BoNTA HC was confirmed experimentally using FP. The EC50 for APM-BDP and 6-AFLU 
were estimated from dose-response curves to be equal to 20.96 ± 10 nM and 546 ± 60nM, 
respectively. The binding of APM and APM-BDP at the same site in BoNTA LC was verified 




The development of an easy, rapid and reliable technique for detection of BoNT in 
contaminated food and body samples is very desirable since MLA is the standard procedure to 
detect BoNTs. BoNTA detection in the primary stage of contamination is critical since the 
antitoxin (the only treatment available) can only be effective if given before entrance of the toxin 
into the nerve cells. The detection time of MLA is between 2-4 days which is the major 
limitation of this technique. MLA required animal facility which makes it more expensive and 
complicated compared to FP. Simplicity of FP assay makes it suitable for high throughput 
screening of large number of samples. FP technique is also suitable for portable devices. In this 
research, the strength of FP assay for detection was confirmed by testing the three identified 
fluorescent probes against BoNTA LC and HC individually, and testing APM-BDP and PAC-
BDP against BoNTA LC and HC in competition assays. In addition, most studies reported in the 
literature are focused on detection of BoNTA based on its catalytic activity. However the active 
site is only accessible after activation of the toxin (cleavage of disulfide bond).Therefore the 
detection of BoNTA using recognition agents that bind to other binding pockets of BoNTA is 
advantageous. The identified fluorescent probes APM-BDP, 6-AFLU and PAC-BDP can be used 
in a multi-probe FP assay to detect BoNTA complex since they bind to the different binding sites 
within the BoNT structure. The application of paclitaxel derivatives in microtubule imaging is a 
limitation of using Paclitaxel-BDP as a recognition agent for BoNTA in cell-based assays. 
However combination of all three fluorescent probes in a multi-probe assay can reduce the 
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Screened library % variance for PC1 
Matrix: Var-covar 
Missing values:  Mean value 
imputation (A) 
% variance for PC1 
Matrix: correlation 
Missing values: iterative 
imputation (B) 
 
Unlabeled library 46.991 48.705 
Fluorescence labeled library 26.997 33.76 
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NMR spectrum of APM-BDP 
 








Total binding versus non-specific binding of radio-ligands against BoNTA LC and HC 
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*These graphs were generated using data before correction of Chromalink effect. 
